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ABSTRACT 
Aneurysmal subarachnoid hemorrhage (aSAH) is a devastating subtype of stroke with 
high mortality and morbidity. aSAH has approximate incidence of 9 cases per 100,000 person-
years, and approximately 1 in 6 patients die during the initial hemorrhage. Further, secondary 
injuries, including cerebral vasospasm and delayed cerebral infarct, are quite common after 
aSAH contributing to the overall mortality rate of nearly 50%. The goal of this study is to gain a 
better understanding of association between aSAH and Haptoglobin genotype (Hp) by 
conducting IPLD meta-analysis. 
Data including 960 subjects from 11 studies were recruited from all published studies 
identified by Pubmed and Web of Science searches, including reference lists within publication, 
and unpublished studies identified via HATCH (Haemoglobin After in TraCranial Haemorrhage) 
consortium and the networks of individual consortium members by the 31st March 2016. 
Given the individual patient level data available, both two-stage and one-stage meta-
analysis were conducted. For two-stage meta-analysis, the primary outcomes were dichotomized 
as unfavorable and favorable outcome, and all secondary outcomes were binary outcomes. 
Logistic regression models were used in the first stage of two-stage meta-analysis to assess the 
association between Hp and aSAH recovery in each study. Generalized estimating equations 
(GEE) with exchangeable correlation were used to fit logistic regression model to estimate the 
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association between Hp and primary outcomes accounting for the correlations between repeated 
measurements over 1, 3, and 6 months for each study in the first stage. Logistic regression 
models were fit via maximum likelihood to assess the association in each study. In second stage, 
meta-analysis via random-effect models was conducted to obtain pooled odds ratio. Q tests and 
I2 were used to test heterogeneity, and to measure possible inconsistency. Publication bias was 
assessed by funnel plots and using the Egger method. In one-stage analyses, mixed effects 
logistic regression was used to generate overall odds ratios using all individual level data from 
different studies simultaneously within one model. 
Both two-stage and one-stage meta-analyses indicated there was no significant 
association between Hp and aSAH. Although Q tests showed there was no heterogeneity, I2 in 
some studies were large, which indicated that the majority of the variability across studies were 
due to heterogeneity instead of chance. In the test of publication bias, both funnel plot and Egger 
test indicated there was no publication bias issue. 
Public Health Significance: There were inconsistent findings from the literature regarding the 
association between Hp and outcome of aSAH. The work here investigates the relationship 
between haptoglobin genotype and outcomes after aSAH using meta-analysis based on current 
literature reports. While our findings were negative, there are a small number of studies with 
fairly small simple sizes, so results may still inform efforts at effective personalized preventive 
care and disease treatments with better specificity, targeted to the genetic makeup of each 
patient. 
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1.0  INTRODUCTION 
1.1 ANEURYSMAL SUBARACHNOID HEMORRHAGE 
In the United States, Subarachnoid hemorrhage (SAH) is responsible for 5% to 10% of all 
strokes and a greater loss of productive life. People of younger age are more likely to suffer SAH 
compared to other subtypes of stroke [1]. An intracranial aneurysm (also known as cerebral 
aneurysm) is a weakened, dilated area of a blood vessel in the brain that is prone to burst. The 
rupture of a cerebral aneurysm causes 85% spontaneous SAH. Although bleeding from small 
aneurysms causes most cases, larger aneurysms are more likely to rupture [2]. 
Aneurysmal subarachnoid hemorrhage (aSAH) is a subtype of devastating stroke that 
occurs at an early age. Because of initial bleeding and subsequent neurovascular events, aSAH 
has high mortality and morbidity [3, 4] with global health burden and permanent disability rates 
[5]. These events have a high mortality, with about 1/6 of  aSAH patients dying during the initial 
bleed [6]. Severe headache of rapid onset, vomiting, decreased level of consciousness, fever, and 
seizures are all the common symptoms of aSAH [7].  Cerebral vasospasm (CV) and delayed 
cerebral ischaemia (DCI) are common and serious complications of aSAH, and together they 
contribute to the poor short-term (first month) outcomes profile after aSAH [8]. The long-term 
outcome and functional status after aSAH are poor with significant morbidity [8]. 
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1.1.1 Epidemiology 
The estimated overall incidence of aSAH is about 9 per 100,000 person-years. Japan (22.7 per 
100,000 person-years), and Finland (19.7 per 100,000 person-year) have much higher rates than 
South and Central America (4.2 per 100,000 person-year), and other regions (9.1 per 100,000 
person-year). Rates increase with increasing age, with age groups older than 85 years having the 
highest rate. Gender differences starts at age 55 years and increase thereafter. The overall 
incidence in women was 1.24 times higher than in men [9].  
In the United States, the incidence of new cases of aSAH is about 30,000 per year [10]. 
From 1988 to 2010, the incidence of aSAH in the United States did not show a statistically 
significant increase (p=0.22), indicating stable incidence. However, 5-day, 30-day, and 90-day 
case-fatality rates have declined significantly over this time period. This reduction is likely due 
to advances in surgical and medical management, and systems-based changes including the 
emergence of neurocritical care units [3].  
1.1.2 Assessment of Severity 
Numerous tools, including the Hunt and Hess Scale, Fisher Scale, Glasgow Coma Score (GCS), 
and the World Federation of Neurological Surgeons Scale (WFNS) are used for assessment and 
prognostication of patients with aSAH. Most of these scales were derived retrospectively [11]. 
The GCS was originally designed to quantify responsiveness and clinical-exam after 
traumatic brain injury [12]. Since its initial development, it has been used as a standard tool to 
quantify neurologic status and changes in status in many populations.  
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WFNS is one of the most common scales. It quantifies burden based on focal 
neurological deficits and Glasgow Coma Scale (GCS), where higher grades are associate with 
worse outcomes. The GCS has less observer variability than WFNS, and is more commonly used 
in assessing the neurological status [11]. 
The Hunt and Hess scale grades subjects based on clinical examination upon admission 
and predicts outcome [13]. The Fisher scale assigns a grade based on the pattern of blood 
visualized on initial computed tomography (CT) scanning and predicts secondary injury 
(cerebral vasospasm) [11, 14]. 
1.2 HAPTOGLOBIN 
As the most abundant protein in erythrocytes and blood, Haptoglobin (Hp) protein binds free 
hemoglobin and facilitates its removal from the bloodstream [15]. It is a unique acute phase 
protein that primarily scavenges haemoglobin (Hb) released into the circulation by haemolysis or 
normal red blood cell (RBC) turnover [16]. The Hp protein is encoded by two genes on 
chromosome 16; the Haptoglobin α and β gene. The gene for the β-chain has no known genetic 
variability. However, the gene for the α-chain has two common alleles, α-1 and α-2 [17]. A 
common 1.7kb copy number variant (CNV) inside the HP gene determines the copy number of a 
tandem two-exon segment including sequence that encodes a multimerization domain [18]. 
In human populations, the α-chain alleles 1 and 2 of haptoglobin (Hp) molecule account 
for three common genotypes and phenotypes: the homozygous Hp1-1 (dominant), Hp2-2 
(recessive) and the heterozygous Hp2-1. These three phenotypes, which determined by two 
alleles Hp1 and Hp2, have biologically significant difference in their antioxidant, scavenging, 
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and immunomodulatory properties and may therefore influence the course of inflammatory 
disease [16, 19]. In most cases, the Hp2 is a less efficient antioxidant than Hp1, and is required to 
make the tight-junction modulator protein zonulin, which is the preprocessed product of Hp2 
[18]. As aSAH is a condition where there is significant blood outside the vasculature and initiates 
a strong inflammatory response, many groups have set out to determine the role genetic 
variability in the Hp gene has on short and long term recovery after aSAH. 
1.3 GOAL 
Hp gene polymorphism effects have been reported prominently in the literature exploring 
outcomes after aSAH. While some studies have found the Hp-2 allele associates with worse 
recovery [20-23] there are inconsistent findings from the literatures [24]. The goal of this study is 
to investigate the relationship between haptoglobin genotype and outcomes after aneurysmal 
subarachnoid hemorrhage. Meta-analysis will be used in examining associations from the current 
literatures. Both two-stage and one-stage meta-analysis will be used. In two-stage analysis, 
Generalized Estimating Equation (GEE) will be used to fit logistic regression models to assess 
the odds ratio in each study controlling for important demographics and clinical variables in 
primary outcomes, which are observed at multiple time points, and maximum likelihood will be 
used to fit logistic regression models to assess the secondary outcomes, which are assessed at one 
time per-subject. The results from each individual study will be pooled together in the second 
stage analysis. One-stage meta-analysis will be also conducted to examine the association 
between Hp and outcome after aSAH given the availability of individual patient level data. 
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2.0  METHODS 
2.1 STUDY DESIGN AND SUBJECTS 
This study is a retrospective study and includes data collected from 11 studies who satisfied 
criteria including: (1) subjects with diagnosis of aSAH; (2) subject who are at least 18 years old; 
(3) haptoglobin genotype or phenotype available; (4) outcomes were measured within 1 month 
(+/- 2 weeks), 3 months (+/- 1.5 months) and 6 months (4.5 months to 12 months) of the aSAH 
(if more than one outcome is available within each of these time frames, the one closest to 1, 3 or 
6 months will be utilized). Data was extracted from all published studies identified by Pubmed 
and Web of Science searches, including reference lists within publication, and unpublished 
studies identified via the HATCH (Haemoglobin After in TraCranial Haemorrhage) consortium 
and the networks of individual consortium members by the 31st March 2016. 
Initial study data included information from available electronic medical records. These 
data included demographic information such as age, gender and race. Subjects outcomes, 
including Glasgow Outcome Score (GOS) and Modified Rankin Score (mRS) were measured 1 
month, 3 months and 6 months. Data for analysis consisted of 960 subjects from 11 studies. Only 
21 subjects had conservative aneurysmal treatment and were excluded from our analysis. 
Analysis with different comparisons of Hp genotype were conducted (Hp-22 vs Hp-11 & 
Hp-21, Hp-11 vs Hp-21 & Hp-22; Hp-11 vs Hp-22; Hp-22 vs Hp-21; Hp-21 vs Hp-11). For 
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primary outcomes, both longitudinal analysis and cross-sectional analysis at each time points 
were conducted. This paper will focus on the effect of Hp-22 versus Hp-11 and Hp-21 on aSAH 
with longitudinal analysis on primary outcomes and cross-sectional analysis on secondary 
outcomes. 
2.2 INDEPENDENT VARIABLES 
2.2.1 Demographic variables 
• Age, gender and race 
All subjects were at least 18 years old with average age of 54.33 and there were slight difference 
across studies. The average age of the subjects in study B was greatest (62.14) and study E was 
youngest group (50.76). There were slightly more females than males in this whole study: 
31.16% male and 68.85% female, as is common in aSAH. Most subjects were white/caucasian 
(70.56%). However, there were some minorities: black (15.28%), Asian (11.46%), and 2.7% 
subjects reported of ‘other’ race.  
• Aneurysmal Treatment 
The most common treatments of cerebral aneurysms are neurosurgical clipping and endovascular 
coiling. These treatments have similar outcomes, but the influence of these treatment modalities 
is still judged controversially [25]. Historically, early surgical treatment was thought to decrease 
angiographic vasospasm and delayed ischemic neurological deficit (DIND) by removing 
subarachnoid blood [26]. However, some studies showed no significant difference in the degree 
of angiographic vasospasm between the surgical and other treatments. It has been suggested that 
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the effect of clot removal may be offset by the negative aspect of early surgery, like brain 
retraction [26, 27].  
Aneurysmal treatment is a main covariate in this study. Most subjects received 
neurosurgical clipping or endovascular coiling, and only 21 subjects received conservative 
treatment. In this study, subjects with conservative treatment, who have worse outcomes, were 
removed and the analysis only focused on subjects with endovascular or surgical treatment.  
• Aneurysmal Sites 
Among patients with aSAH, the location of aneurysm was classified in 5 categories: (1) the 
anterior communicating artery (AcoA); (2) the distal anterior cerebral artery (ACA); (3) the 
internal carotid artery (ICA); (4) the middle cerebral artery (MCA); (5) the vertebrobasilar artery 
(VBA).  Without considering age, ACoA aneurysms are more common in men, whereas ICA 
aneurysms are more likely to happen among women [28, 29]. 
 In this study, we had aneurysm site data from 882 subjects. Among these subjects, the 
majority were ICA (26.98%) and ACA (40.14%) aneurysms, and 32.88% of aneurysms were 
from MCA (16.44%) and VBA (16.44%). 
• Diabetes 
Diabetes mellitus (DM) is a group of metabolic disorders in which there are high blood glucose 
levels over a prolonged period [30]. It is reported that the diabetic patients have 1.7 times higher 
probability to have cerebrovascular disease than nondiabetic persons. However, some studies 
reported a decreased association between diabetes mellitus and aSAH risk [31]. The healthier 
lifestyle DM patients have may be the reason for the lower risk [32]. Only 9.26% subjects in this 
study with DM, which is much lower than subjects without. 
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• Hypertension 
Hypertension (HTN) is defined by the presence of persistently elevated blood pressure, which 
usually leads to morphological and functional changes in the heart and systemic arterioles [33]. 
From the numerous studies of aSAH, HTN is one of the most controvertible factor to cause 
aSAH. However, according to multivariate analysis, HTN is not an independent risk factor for 
aSAH [34]. In this study, about half subjects had HTN (46.24%). Study E had the least HTN 
patients with only 26.63% of the total. 
2.2.2 Clinical variables 
• Glasgow Coma Score (GCS) 
The GCS is a common tool to quantify neurologic function in acutely ill or injured patients. It 
was originally designed to assess level of consciousness after traumatic brain injury [12], but it is 
now used in many other populations with potential brain injury. The GCS assigns numeric scores 
to a patient best eye opening, verbal and motor response in response to stimuli. GCS ranges 3 
(deep coma) to 15 (awake and alert). 
• Fisher Grade 
The Fisher Grade is widely accepted in assessment of the extensiveness of aSAH and the 
presence of other intracranial hemorrhage on the CT scan [14]. The Fisher Grade assigns 
individuals to one of four broad outcome categories: Grade 1- no SAH visualized; Grade 2 – thin 
layer of SAH, less than 1 mm thick; Grade 3 – focal or diffuse layer of SAH, greater than 3 mm 
in thickness; Grade 4 – intracerebral or intraventricular clots with or without SAH [35]. In this 
study, we adjusted Fisher Grade by combing grade 1 and 2 as one group, and grade 3 and 4 as a 
second group. There are only 20.2% subjects without or with thin layer of SAH in our analysis. 
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• World Federation of Neurosurgical Societies (WFNS) 
WFNS grading system is a five-step grading scale based on a preoperative clinical condition for 
predicting further outcomes. In 1988, the grading scale was established by the Executive 
Committee of WFNS. There are 5 grades in WFNS, and the increasing grade is associated with 
worse outcome. For example, grade V denotes strongly predictive for extremely poor outcome 
[36].  
 In this study, WFNS was dichotomized into good grade (WFNS 1 - 3) which indicates a 
favorable outcome or poor grade (WFNS 4 - 5) which indicates a poor outcome. There were 837 
subjects in this study with WFNS, and 71.68% of them had a good grade. 
• Hunt and Hess (H&H) 
Hunt and Hess is a commonly used way to assess the clinical severity of SAH [37]. The H&H 
quantifies disability using an ordinal hierarchical grading from zero to 5, and the increasing 
grade is associated with worse outcome. Patients with severe H&H (4 and 5) have fared poorly 
and generally consist of approximately 20% - 30% of those admitted to the hospital with aSAH 
[38]. 
 In this study, H&H was dichotomized into good grade (H&H 0-3) and poor grade (H&H 
4-5). There were 140 (27.66%) patients in the study with H&H and 366 (72.34%) with good 
outcome.  
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2.3 OUTCOME VARIABLES 
2.3.1 Primary Outcome 
• Modified Rankin Scale (mRS)
 
and the most common measure in landmark studies. The mRS quantifies disability using an 
ordinal hierarchical grading from zero to six, and the increasing grade indicates poorer 
outcome. Zero indicates no symptoms and 6 indicates death [39].  
In this study, the outcome variable of interest was 1, 3, and 6-month mRS. The mRS was 
dichotomized into favorable (mRS 0-2 [good recovery, no significant disability, slight 
disability]) or unfavorable (mRS 3-6 [moderate disability, moderately severe disability, severe 
disability, or death]) as is often done in the aSAH literature to maximize power. In studies A, B, 
C, D, F, G, and I there was information on mRS, and we used it as the primary outcome in our 
analysis.  
• Glasgow Outcome Scale (GOS)
The GOS is one of the most widely used outcome measure after traumatic brain injury in clinical 
settings because it is easy to administer. GOS uses an ordinal hierarchical grading and is divided 
into five categories: dead, vegetative state, severe disability, moderate disability, and good 
recovery. The increasing grade indicates better outcome [40]. 
In this study, the outcome variable of interest was 1, 3, and 6-month GOS. The GOS was 
dichotomized into favorable (GOS 4-5 [moderate disability or good recovery]) or unfavorable 
(GOS 1-3 [death, vegetative state, or severe disability]) as is often done in the literature to 
 The mRS is one of the most prevalent functional outcome measure in contemporary stroke trials
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maximize power. Study A, C, D, E, F, G, and I had information of GOS, and we used them in 
further analysis. 
 The primary outcome was defined mainly as mRS, which was used in most analysis. 
However, Study E used GOS as primary outcome because it didn’t have mRS information. In 
this study, mRS in Study A, B, C, D, F, G, I and GOS in Study E were combined in the analysis 
of the primary outcome. 
2.3.2 Secondary Outcomes 
aSAH may induced cerebral vasospasm, a decrease in the internal lumen of the cerebral blood 
vessels that is commonly diagnosed with angiography. About 30% - 70% aSAH patients have 
angiographic cerebral vasospasm, and about 50% of them have delayed neurologic ischemia 
resulting in permanent deficits from ischemic stroke or death [41]. 
 
• The presence of Delayed Ischemic Neurological Deficit (DIND) 
DIND, resulting from cerebral vasospasm, is common after aSAH and contributes to the high 
morbidity and mortality [42, 43]. DIND is defined as a new focal neurologic deficit or a drop in 
GCS of greater than 2 not temporally related to the treatment of the aneurysm and not due to 
other cases, such as hyponatremia, infection and others. The biological process underlying DIND 
remains unclear, but some studies suggest that DIND is induced by cerebral vasospasm and 
additional factors after SAH. Patients that develop DIND always have higher Hunt and Hess 
grade and more often are classified as Fisher Grade 3 [43]. 
 In our study, less than half (35.87%) of the subjects had DIND. Study A, B, C, D, G, and 
I had DIND information, and we did analysis in these studies. 
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• The presence of Radiological Infarct after aSAH  
Silent infarction is common in aSAH patients, and always associated with poor outcome. It can 
be detected by invasive neuromonitoring devices because of the changes in cerebral metabolism 
and oxygenation. Compared those with distant or no ischemia, patients with infarction have 
lower lactate-pyruvate-ration elevation and brain glucose. These concepts are used as evidence in 
clinical research [44] but radiographic evidence (CT or magnetic resonance imaging) of 
infarction is used for clinical care. For this analysis, Radiographic Infarction was verified based 
on CT or MR evidence of ischemia 
 In this study, about 30% subjects had the presence of radiological infarct, and Study A, 
B, C, D, and G had this data. 
 
• The presence of angiographic evidence of vasospasm 
Vasospasm, a reduction of the internal lumen of the cerebral blood vessels, results in reduced 
blood flow and an increase in blood flow velocity after aSAH. The clinical vasospasm includes 
vasospasm identified by angiography or transcranial doppler ultrasonography and new onset of 
neurologic deficit and contributes to delayed ischemic neurologic deficit; and delayed cerebral 
ischemia [45]. 
Delayed cerebral ischemia (DCI) is a specific subtype of ischemic stroke among patients 
who survive from aneurysmal subarachnoid hemorrhage. This stroke usually develops about one 
week after aneurysm rupture. Studies confirmed an association between DCI and angiographic 
vasospasm [46], and prevention or treatment of angiographic vasospasm after aSAH may 
mitigate its sequelae [47].  
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 In this study, about 40% subjects had the presence of angiographic evidence of 
vasospasm, which is a little bit higher than the presence of DIND and radiological infarct. Study 
A, D, E, F, G, and I had this data. 
• The presence of Transcranial Doppler Sonography (TCD) evidence of vasospasm 
TCD is a noninvasive ultrasound diagnostic method to monitor the state of intracerebral 
hemodynamics [45]. It is used to quantify cerebral blood flow velocity in the large cerebral blood 
vessels and may infer cerebral vasospasm. However, because of high rate of false negative 
results likely due to micro vessel vasospasm and not detected with TCD, there are many 
criticisms about TCD’s detecting ability. 
 In this study, we defined subjects with “definite vasospasm” as TCD higher than 200cm/s 
as vasospasm. Around 40% patients had the presence of TCD evidence of vasospasm based on 
our criteria, which is almost same as the percentage of presence of angiographic evidence of 
vasospasm. Study B, C, D, F, I, J, and K had data of this information,  
2.4 DATA ANALYSIS 
Data were from 11 different studies and were merged into a single file with variable coding 
standardized (e.g. female sex=1) for each individual. Upon receiving the Excel file containing 
the raw data, data management and analysis were done, including a comprehensive review of all 
raw data, cleaning of the dataset and performing all statistical analysis including modelling and 
graphical analysis. 
Statistical analyses were performed in STATA software (version 14.0 SE StataCorp, 
College Station, TX). Descriptive analysis included computing means and standard deviation for 
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all continuous variables, and frequencies and percentages for all categorical variables in each 
study.  
Two-stage and one-stage meta-analysis were conducted. In the first step of two-stage 
analyses, the primary outcome mostly uses mRS except Study E which uses GOS. GEE was used 
to fit logistic regression models in analysis of the primary outcome because of repeated 
measurements. Secondary outcomes were only measured once so logistic regression models were 
fit via maximum likelihood. Instead of simply dichotomizing primary outcomes at one fixed 
point, sensitivity analysis including a sliding dichotomy and proportional odds logistic regression 
model were also conducted for the primary outcome, with the aim of avoiding information loss 
about the outcome and reducing statistical power. Meta-analysis with random-effects was used in 
the secondary step. In the diagnosis of meta-analysis, the heterogeneity was tested by Q tests and 
I2, and publication bias was measured by funnel plot and Egger’s test. 
In the one-stage analyses, mixed effect logistic regression models were used to generate 
overall odds ratios by utilizing all the data from all studies in one step adjusting for the 
covariates. In both primary and secondary outcomes, each study was considered as a cluster. In 
the primary outcomes, each subject was also considered as a cluster because of repeated 
measurements. 
In the adjusted analysis after controlling other covariates, the following minimal core 
covariates were used: 1. Age; 2. Fisher, dichotomized into 1+2 and 3+4. 3. WFNS dichotomized 
into good and poor grade; 4. Treatment, categorized into clipping and coiling; and 5. Time (used 
in longitudinal modelling).  Where possible, allowing for sample size and data availability, 
additional covariates will be used, prioritized in the following order: 1. Diabetes; 2. 
Hypertension; 3. Race; and 4. Aneurysm site.  
15 
2.4.1 Hardy-Weinberg equilibrium 
Hardy-Weinberg equilibrium is used to describe the relationship between allele frequency and 
genotype frequency in a population. OEGE (Online Encyclopedia for Genetic Epidemiology 
studies) was used to test if Hp in all studies follow the Hardy-Weinberg equilibrium. Chi-square 
Hardy-Weinberg equilibrium test calculator for biallelic markers (SNPs, indel etc), including 
analysis for ascertainment bias for ascertainment bias for dominant/recessive models (due to 
biological or technical causes) was used. P-values were calculated with 1 degree of freedom.  
2.4.2 Longitudinal Modelling 
The longitudinal study is a research design that involves repeated observations of the same 
variables over a periods of time [48]. In a longitudinal study, the outcome has been measured 
several times, and the result of each in one subject is correlated.  
GOS and mRS were measured three times (1 month, 3 months, and 6 months) in this 
study, so longitudinal analysis was needed. For each subject, the result of mRS or GOS in 
different time point were correlated. If both mRS and GOS were available for the same dataset, 
mRS will be used. 
2.4.3 Generalized Estimating Equation (GEE) 
The GEE, which was introduced by Liang and Zeger (1986), is a method that can be used to 
estimate marginal or population-averaged effects taking into account the dependence among 
observations within a subject. It is usually done by specifying working correlations Ri for the 
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observed outcomes (conditional on covariates). In this study, with many clusters (960 subjects) 
and relatively few observations per cluster (1, 3, and 6 months per subject), the GEE method was 
used to adjust replicated primary outcomes within subjects at three time points in the first stage 
of the two-stage meta-analysis. However, the GEE method is limited to a single level of 
clustering, so it cannot be used in one-stage meta-analysis in this study. 
 The formulation of a model of mean μij, which indicate the subject i at time j, depends 
upon regression parameters βk, and variance structure Vi is as following [49]: 
 
 
 
The GEE is based on the concept of estimating equations and provides a general 
approach to analyze correlated responses, and this idea is to generalize the cross-sectional 
likelihood estimating equations of a Generalized Linear Model (GLM) by incorporating the 
covariance matrix of the responses. Using the GEE approach, we do not need to specify a model 
for the whole multivariate distribution of the data. Instead, it models the mean response E(Yi) 
and the covariance matrix Vi as in the normal case. 
A feature of GEE is that marginal effects can be consistently estimated, even if the 
dependence among observations within subjects working correlations Ri is not properly 
specified. However, GEE does assume that the model for the mean is correct. Misspecification of 
the mean model could lead to biased results. 
 In the analysis of the relationship between Hp and mRS or GOS, GEE was used to 
estimate odds ratio between different Hp genotypes and primary outcome. The family was 
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binomial because the outcome was binary (1-unfavorable; 0-favorable), and the logit link was 
used. 
2.4.4 Mixed Model 
A mixed model is a statistical model containing both fixed effects and random effects. The 
process for fitting the mixed model involves estimating the fixed effects, estimating the random 
effects and estimating the variance parameters. 
In this study, mixed effect logistic regression models were used in one-stage analysis. 
Each study was considered as a cluster in analysis. The primary outcomes were in a longitudinal 
dataset with three time points, and each subject was also considered as a cluster. 
2.4.5 Logistic regression 
Logistic regression was used to model the dichotomous/binary outcomes. Given a probability p, 
the logit is defined as 
 
Since  is what defined as the odds, the logit is also known as the log-odds. There is a 
one-to-one correspondence between p and logit(p). 
Given a value of a logit(p) = θ, the probability can be computed. The inverse of the logit 
is known as the expit: 
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In cross sectional analysis of secondary outcomes and some primary outcomes with one 
time point, the time effect was not considered. The logistic regression model is used in this 
analysis to find the odds ratio between different Hp. 
2.4.6 Sliding Dichotomy 
In the previous analysis, the mRS and GOS were divided into two groups: mRS 0-2 to 3-6 and 
GOS 1-3 to 4-5, and all subjects dichotomized at the fixed point. The statistical analysis and 
interpretation of the results are simple, but with issue of loss of information about outcome and 
reduced statistical power [50]. 
One method has been proposed to avoid these problem is the sliding dichotomy. A single 
binary outcome, as assessed by the GOS or mRS, dichotomized into favorable and unfavorable 
using a cut point depending on the predicted prognosis for an individual patient on entry into the 
study. For example, only a good recovery might be considered as favorable outcome for a patient 
predicted to have a good recovery; similarity, severe disability might be regarded as a favorable 
outcome for a patient predicted to die or be in a vegetative state [50]. If both mRS and GOS are 
available for the same dataset, mRS will be used. Regarding analysis, we first estimated the 
baseline prognostic risk in each patient by calculating the probability of a favorable outcome 
using a predictive model with the covariates (listed above) adjusted for in each data set in a 
logistic regression model. Then, patients were grouped into three prognostic cluster of 
approximately equal sample size based on the tertiles of prognostic scores: best, intermediate, 
and worst prognosis.  
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For each band, a separate cut point on either the GOS or the mRS was defined and a new 
outcome variable was created. For a sliding or logical cut point, favorable outcome was defined 
in the worst tier as score 3-5 in GOS; 4-5 in the intermediate tier, and only 5 in best tier. For the 
mRS, favorable outcome in the worst tier included good recovery, no significant disability, slight 
disability, moderate disability, and moderately severe disability; good recovery, no significant 
disability, slight disability, and moderate disability in intermediate tier; and good recovery, no 
significant disability, and slight disability in the best tier [50]. Binary logistic regression was 
used, with stratification by prognostic bands. The pooled sliding dichotomy odds ratio was 
calculated as the summary effect of Hp on outcomes. 
2.4.7 Proportional odds logistic regression model 
Proportional odds logistic regression is another way to avoid theoretical issues. It can be used to 
estimate the covariate effects and the relative probabilities of outcomes in ordinal categories 
variable.  
 The ordinal mRS and ordinal GOS were analyzed separately: For patients with mRS 
outcome, the ordinal mRS was considered in a 5 point ordinal scale (mRS larger or equal to 4 
were combined into one level); For patients with GOS outcome, the ordinal GOS was considered 
in a 3 point ordinal scale (GOS less or equal to 3 were combined into one level). The 
proportional odds logistic regression model was used in this analysis. The proportional odds 
logistic regression estimates a common odds ratio for each of the possible cut points of the 
outcome scale [50]. The common odds ratio is formally valid if the odds ratios for each cut point 
are the same. The common odds ratio can be interpreted as a summary measure of Hp effect on 
outcomes. 
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2.4.8 Meta-Analysis 
The meta-analysis is a statistical analysis that combines the results of several independent studies 
and derive a pooled estimate to get an common result [51]. With the odds ratio of Hp effect on 
outcomes in each study, Meta-Analysis was used to get the common odds ratio among all studies 
centers. 
There are fixed (common) effect meta-analysis and random effect meta-analysis. In fixed 
effect analysis, it is assumed that the effect of Hp is the same across different studies. But in 
random effect analysis, it is assumed that the true effect of Hp in each study is randomly, 
normally distributed between studies. To estimate the between-study variance τ2 and modify the 
weights in each study, the DerSimonian and Laird estimate is mostly used. The equation of 
random effect estimate is as following. 
 
Where, 
 
 And the variance of random-effects summary OR is. 
 
This study used Meta-analysis of individual participant data (IPD), which obtained and 
synthesized the raw individual level data from multiple related studies. This approach is 
becoming an increasingly popular tool as an alternative to traditional aggregate data Meta-
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analysis [52]. There are both statistical and clinical advantages of this approach, including 
increasing the power to detect differential treatment effects across individuals in randomized 
trials, and allowing adjustment for confounding factors in observational studies [53]. Also, the 
subgroup effects at an individual level can be examined [54]. It is most used when a Meta-
analysis of aggregate data cannot reliably answer the clinical questions, with aim to summarize 
the evidence on a particular clinical question from multiple related studies [53]. For example, 
this study was focused on whether Hp genotype effects the outcome after aSAH. 
There are some requirements of individual participant data for Meta-analysis. Firstly, it 
should be protocol based, clearly reported, driven by clinical questions. Secondly, this statistical 
implementation must preserve the clustering of patients within studies. Analyzing IPD as if they 
all came from a single study is inappropriate and will cause some problems. 
Two statistical approaches including one-stage and two-stage are commonly used in IPD 
Meta-analysis. Two-stage analysis considers each study independently by appropriate model and 
combines these in a traditional Meta-analysis model. Two-stage approach is more laborious, but 
easier to be understand because it uses standard Meta-analysis methods in the second step [52, 
53].  
One-stage approach conveniently requires only a single model and analyzes all studies 
simultaneously, which may increase complexity for non-statisticians and requires careful 
separation of within study and between study variability. However, this approach uses a more 
exact likelihood specification, which avoids the assumption of within-study normality and 
known within-study variance. It is commonly used in small studies and/or rare events [52, 53]. 
The result of one-stage and two-stage approach may different and most of difference are 
result of different modelling assumptions, which including the specification of the likelihood and 
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included parameters, the choice of random or fixed effects. Meanwhile, choosing a different 
estimation procedure is another reason for this difference. However, these two approaches will 
result very similar conclusions when the same assumptions are made and the same estimation 
procedures are used [52].  
The usual test (Q test) and I2 are two common ways to test the heterogeneity and 
conclude consistency of meta-analysis. The statistic of Q test follows χ2 distribution with k-1 
degree of freedom where k is the number of studies. The I2 is the degree of inconsistency in the 
study’s results which is an alternative approach to quantify the effect of heterogeneity. I2 
describes the percentage of total variation across studies that is due to heterogeneity rather than 
chance, and it is obtained as I2=100%*(Q-df)/Q, where Q is Cochran’s heterogeneity statistics. I2 
always between 0% and 100%, and the heterogeneity increases with larger values. When I2 is 0% 
means no heterogeneity is observed [55]. There are widely used benchmarks for I2. For example, 
I2 values of 25%, 50%, and 75% are always interpreted as representing small, moderate and high 
level of heterogeneity. 
In STATA, heterogeneity is calculated by following formula. 
 
 Where, 
 
Publication bias occurs when considering the representativeness of any given study or set 
of studies that have significant outcome as these are more likely to be published. Tests for the 
asymmetry of funnel plots and methods based on selection models are the most common types of 
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the statistical methods that assess the publication bias. In this study, both funnel plot and Egger’s 
regression method were used [56]. 
A Funnel plot is a graph designed to check for the existence of publication bias and is 
commonly used in systematic review and meta-analysis. In the absence of publication bias, it 
assumes that the largest studies will be plotted near the average, and smaller studies will be 
spread evenly on both sides of the average, creating a roughly funnel-shaped distribution. 
Deviation from this shape can indicate publication bias. A funnel plot is a scatterplot of treatment 
effect against a measure of study size. It is used primarily as a visual aid for detecting bias for 
systematic heterogeneity. A symmetric inverted funnel shape arises from a “well-behaved” data 
set, which is not likely to have publication bias. On the contrary, an asymmetric funnel indicates 
a relationship between treatment effect estimate and study size. This suggests the possibility of 
either publication bias or a systematic difference between smaller and larger studies.  
Asymmetry can also arise from use of an inappropriate effect measure. Whatever the 
cause, an asymmetric funnel plot leads to doubts over the appropriateness of a simple meta-
analysis and suggests that there needs to be investigation of potential causes.  The asymmetry of 
funnel plot can be tested by Egger’s regression method, which is algebraically identical to a test 
that there is no linear association between the treatment effect and its standard error and indicate 
that there is no straight-line association in the funnel plot of treatment effect against its standard 
error. 
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3.0  RESULT 
3.1 DESCRIPTIVE CHARACTERISITICS 
3.1.1 Demographics 
A detailed description of the demographics variables by study group assignment is presented in 
Table 1, which including: age, gender, admission WFNS, fisher grade on initial CT, aneurysmal 
treatment. The age of subjects was 54.34 with standard deviation 13.09. Other descriptive 
characteristics of demographics variables were shown in Table 1. Table 1 also indicated that 
there was missing data for several variables. 
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Table 1. Descriptive statistics for demographics variables 
 A (n=37) B (n=95) C (n=86) D (n=55) E (n=169) F (n=143) G (n=46) H (n=37) I (n=192) J (n=30) K (n=49) All (n=939) 
age            934 
(99.47%) 
Mean 
(SD) 
59.49 
(13.0) 
62.14 
(13.74) 
54.36 
(14.34) 
54.14 
(12.93) 
50.76 
(11.61) 
53.70 
(13.91) 
53.49 
(12.92) 
52.49 
(15.66) 
54.42 
(11.16) 
51.53 
(12.80) 
53.20 
(11.23) 
54.34 
(13.09) 
Sex             934 
(99.47%) 
Male 13 
(35.14%) 
42 
(44.21%) 
26 
(30.23%) 
13 
(23.64%) 
57 
(33.73%) 
36 
(26.09%) 
14 
(30.43%) 
14 
(37.84%) 
55 
(28.65%) 
10 
(33.33%) 
11 
(22.45%) 
291 
(31.16%) 
Female 24 
(64.86%) 
53 
(55.79%) 
60 
(69.77%) 
42 
(76.36%) 
112 
(66.27%) 
102 
(73.91%) 
32 
(69.57%) 
23 
(62.16%) 
137 
(71.35%) 
20 
(66.67%) 
38 
(77.55%) 
643 
(68.84%) 
WFNS            837 
(89.14%) 
0 12 
(32.43%) 
57 
(60.00%) 
55 
(63.95%) 
34 
(61.82%) 
155 
(91.72%) 
87 
(62.59%) 
31 
(70.45%) 
17 
(85.00%) 
152 
(79.17%) 
0 
(0.00%) 
0   
(0.00%) 
600 
(71.68%) 
1 25 
(67.57%) 
38 
(40.00%) 
31 
(36.05%) 
21 
(38.18%) 
14   
(8.28%) 
52 
(37.41%) 
13 
(29.55%) 
3 
(15.00%) 
40 
(20.83%) 
0 
(0.00%) 
0   
(0.00%) 
237 
(28.32%) 
Fisher            901 
(95.95%) 
0 0 
(0.00%) 
9 
(9.57%) 
7 
(8.14%) 
12 
(21.82%) 
45 
(26.63%) 
50 
(36.50%) 
3 
(5.82%) 
2 
(25.00%) 
54 
(28.13%) 
0 
(0.00%) 
0   
(0.00%) 
182 
(20.20%) 
1 37 
(100%) 
85 
(90.43%) 
79 
(91.86%) 
43 
(78.18%) 
124 
(73.37%) 
87 
(63.50%) 
41 
(93.18%) 
6 
(75.00%) 
138 
(71.88%) 
30 
(10.00%) 
49 
(100.00%) 
719 
(79.80%) 
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Table 1 Continued 
 A (n=37) B (n=95) C (n=86) D (n=55) E (n=169) F (n=143) G (n=46) H (n=37) I (n=192) J (n=30) K (n=49) All (n=939) 
Treatment            889 
(94.68%) 
endovascular 32 
(86.49%) 
22 
(23.16%) 
41 
(47.67%) 
35 
(63.64%) 
143 
(85.12%) 
25 
(20.00%) 
31 
(67.39%) 
3 
(50.00%) 
115 
(59.90%) 
13 
(43.33%) 
17 
(34.69%) 
477 
(53.66%) 
surgical 5 
(13.51%) 
73 
(76.84%) 
45 
(52.33%) 
20 
(36.36%) 
25 
(14.88%) 
100 
(80.00%) 
15 
(32.61%) 
3 
(50.00%) 
77 
(40.10%) 
17 
(56.67%) 
32 
(65.31%) 
412 
(46.34%) 
Aneurysm            882 
(93.93%) 
ICA 3 
(8.11%) 
30 
(31.58%) 
24 
(27.91%) 
9 
(16.36%) 
44 
(26.04%) 
45 
(34.62%) 
18 
(40.91%) 
5 
(19.23%) 
55 
(28.65%) 
0 
(0.00%) 
5 
(10.42%) 
238 
(26.98%) 
ACA 15 
(40.54%) 
34 
(35.79%) 
30 
(34.88%) 
28 
(50.91%) 
77 
(45.56%) 
47 
(36.15%) 
13 
(29.55%) 
11 
(42.31%) 
78 
(40.63%) 
0 
(0.00%) 
21 
(43.75%) 
354 
(40.14%) 
MCA 13 
(35.14%) 
18 
(18.95%) 
8 
(9.30%) 
9 
(16.36&) 
32 
(18.93%) 
18 
(13.85%) 
3 (6.82%) 4 
(15.38%) 
25 
(13.02%) 
0 
(0.00%) 
15 
(31.25%) 
145 
(16.44%) 
vertebral-
basilar 
6 
(16.22%) 
13 
(13.68%) 
24 
(27.91%) 
9 
(16.36&) 
16 
(9.47%) 
20 
(15.38%) 
10 
(22.73%) 
6 
(23.08%) 
34 
(17.71%) 
0 
(0.00%) 
7 
(14.58%) 
145 
(16.44%) 
HTN            865 
(92.12%) 
No 18 
(48.65%) 
43 
(45.26%) 
37 
(43.53%) 
27 
(49.09%) 
124 
(73.37%) 
52 
(39.10%) 
19 
(42.22%) 
2 
(25.00%) 
114 
(62.30%) 
18 
(60.00%) 
11 
(44.00%) 
465 
(53.76%) 
Yes 19 
(51.35%) 
52 
(54.74%) 
48 
(56.47%) 
28 
(50.91%) 
45 
(26.63%) 
81 
(60.90%) 
26 
(57.78%) 
6 
(75.00%) 
69 
(37.70%) 
12 
(40.00%) 
14 
(56.00%) 
400 
(46.24%) 
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3.1.2 Clinical Outcome 
All primary and secondary outcome data were categorical data, and Table 2 showed the 
frequency and percentage of each category for each study and the table across all studies.
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Table 2. Descriptive statistics for clinical outcome 
 A (n=37) B (n=95) C (n=86) D (n=55) E (n=169) F (n=143) G (n=46) H (n=37) I (n=192) J (n=30) K (n=49) All (n=939) 
mRS30d            372 (44.20%) 
0 0 
(0.00%) 
22 
(23.16%) 
0  
(0.00%) 
9 
(21.43%) 
0   
(0.00%) 
7  
(6.31%) 
7 
(18.42%) 
0 
(0.00%) 
0   
(0.00%) 
0 
(0.00%) 
0 
(0.00%) 
45 (12.10%) 
1 0 
(0.00%) 
23 
(24.21%) 
8  
(9.30%) 
16 
(38.10%) 
0   
(0.00%) 
22 
(19.82%) 
11 
(28.95%) 
0 
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
0 
(0.00%) 
80 (21.51%) 
2 0 
(0.00%) 
15 
(15.79%) 
5  
(5.81%) 
3 
(7.14%) 
0   
(0.00%) 
25 
(22.52%) 
5 
(13.16%) 
0 
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
0 
(0.00%) 
53 (14.25%) 
3 0 
(0.00%) 
7 
(7.37%) 
33 
(38.37%) 
6 
(14.29%) 
0   
(0.00%) 
21 
(18.92%) 
3  
(7.89%) 
0 
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
0 
(0.00%) 
70 (18.82%) 
4 0 
(0.00%) 
16 
(16.84%) 
16 
(18.60%) 
5 
(11.90%) 
0   
(0.00%) 
18 
(16.22%) 
8 
(21.05%) 
0 
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
0 
(0.00%) 
63 (16.94%) 
5 0 
(0.00%) 
11 
(11.58%) 
14 
(16.28 %) 
3 
(7.14%) 
0   
(0.00%) 
5  
(4.50%) 
2  
(5.26%) 
0 
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
0 
(0.00%) 
35 (9.41%) 
6 0 
(0.00%) 
1 
(1.05%) 
10 
(11.63%) 
0 
(0.00%) 
0   
(0.00%) 
13 
(11.71%) 
2  
(5.26%) 
0 
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
0 
(0.00%) 
26 (6.99%) 
mRS3m            531 (56.55%) 
0 0 
(0.00%) 
32 
(33.68%) 
2  
(2.38%) 
9 
(21.43%) 
0   
(0.00%) 
9 
(15.52%) 
4 
(16.00%) 
0 
(0.00%) 
34 
(17.71%) 
0 
(0.00%) 
0  
(0.00%) 
90 (16.95%) 
1 7 
(20.00%) 
12 
(12.63%) 
24 
(28.57%) 
16 
(38.10%) 
0   
(0.00%) 
23 
(39.66%) 
6 
(24.00%) 
0 
(0.00%) 
57 
(29.69%) 
0 
(0.00%) 
0  
(0.00%) 
145 (27.31%) 
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2 13 
(37.14%) 
13 
(13.68%) 
13 
(15.48%) 
3 
(7.14%) 
0   
(0.00%) 
10 
(17.24%) 
3 
(12.00%) 
0 
(0.00%) 
45 
(23.44%) 
0 
(0.00%) 
0  
(0.00%) 
100 (18.83%) 
3 8 
(22.86%) 
13 
(13.68%) 
18 
(21.43%) 
6 
(14.29%) 
0   
(0.00%) 
6 
(10.34%) 
6 
(24.00%) 
0 
(0.00%) 
16 
(8.33%) 
0 
(0.00%) 
0  
(0.00%) 
73 (13.75%) 
4 4 
(10.81%) 
11 
(11.58%) 
11 
(13.10%) 
5 
(11.90%) 
0   
(0.00%) 
4  
(6.90%) 
3 
(12.00%) 
0 
(0.00%) 
6  
(3.13%) 
0 
(0.00%) 
0  
(0.00%) 
44 (8.29%) 
5 2 
(5.71%) 
12 
(12.63%) 
6  
(7.14%) 
3 
(7.14%) 
0   
(0.00%) 
4  
(6.90%) 
1  
(4.00%) 
0 
(0.00%) 
3  
(1.56%) 
0 
(0.00%) 
0  
(0.00%) 
31 (5.84%) 
6 1 
(2.86%) 
2 
(2.11%) 
10 
(11.90%) 
0 
(0.00%) 
0   
(0.00%) 
2  
(3.45%) 
2  
(8.00%) 
0 
(0.00%) 
31 
(16.15%) 
0 
(0.00%) 
0   
(0.00%) 
48 (9.04%) 
mRS6m            287 (30.56%) 
0 8 
(23.53%) 
20 
(32.79%) 
0  
(0.00%) 
7 
(30.43%) 
0   
(0.00%) 
0   
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
36 
(22.36%) 
0 
(0.00%) 
0  
(0.00%) 
71 (24.74%) 
1 9 
(26.47%) 
15 
(24.59%) 
0  
(0.00%) 
6 
(26.09%) 
0   
(0.00%) 
0  
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
54 
(33.54%) 
0 
(0.00%) 
0  
(0.00%) 
84 (29.27%) 
2 7 
(20.59%) 
13 
(21.31%) 
0  
(0.00%) 
4 
(17.39%) 
0   
(0.00%) 
3 
(50.00%) 
0  
(0.00%) 
0 
(0.00%) 
28 
(17.39%) 
0 
(0.00%) 
0  
(0.00%) 
55 (19.16%) 
3 4 
(11.76%) 
5 
(8.20%) 
0  
(0.00%) 
3 
(13.04%) 
0   
(0.00%) 
0  
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
7  
(4.35%) 
0 
(0.00%) 
0  
(0.00%) 
19 (6.62%) 
4 4 
(11.76%) 
4 
(6.56%) 
0  
(0.00%) 
3 
(13.04%) 
0   
(0.00%) 
3 
(50.00%) 
0  
(0.00%) 
0 
(0.00%) 
2  
(1.24%) 
0 
(0.00%) 
0  
(0.00%) 
16 (5.57%) 
5 1 
(2.94%) 
3 
(4.92%) 
0  
(0.00%) 
0 
(0.00%) 
0   
(0.00%) 
0  
(0.00%) 
1 
(50.00%) 
0 
(0.00%) 
1  
(0.62%) 
0 
(0.00%) 
0  
(0.00%) 
6 (2.09%) 
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6 1 
(2.94%) 
1 
(1.64%) 
0  
(0.00%) 
0 
(0.00%) 
0   
(0.00%) 
0  
(0.00%) 
1 
(50.00%) 
0 
(0.00%) 
33 
(20.50%) 
0 
(0.00%) 
0   
(0.00%) 
36 (12.54%) 
mRS1y            295 (31.42%) 
0 0 
(0.00%) 
22 
(38.60%) 
10 
(13.70%) 
0 
(0.00%) 
0   
(0.00%) 
0   
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
38 
(23.03%) 
0 
(0.00%) 
0  
(0.00%) 
70 (23.73%) 
1 0 
(0.00%) 
14 
(24.56%) 
24 
(32.88%) 
0 
(0.00%) 
0   
(0.00%) 
0  
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
65 
(39.39%) 
0 
(0.00%) 
0  
(0.00%) 
103 (34.92%) 
2 0 
(0.00%) 
13 
(22.81%) 
15 
(20.55%) 
0 
(0.00%) 
0   
(0.00%) 
0  
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
17 
(10.30%) 
0 
(0.00%) 
0  
(0.00%) 
45 (15.25%) 
3 0 
(0.00%) 
3 
(5.26%) 
8 
(10.96%) 
0 
(0.00%) 
0   
(0.00%) 
0  
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
10 
(6.06%) 
0 
(0.00%) 
0  
(0.00%) 
21 (7.12%) 
4 0 
(0.00%) 
4 
(7.02%) 
4  
(5.48%) 
0 
(0.00%) 
0   
(0.00%) 
0  
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
1  
(0.61%) 
0 
(0.00%) 
0  
(0.00%) 
9 (3.05%) 
5 0 
(0.00%) 
0 
(0.00%) 
1  
(1.37%) 
0 
(0.00%) 
0   
(0.00%) 
0  
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
1  
(0.61%) 
0 
(0.00%) 
0  
(0.00%) 
2 (0.68%) 
6 0 
(0.00%) 
1 
(1.75%) 
11 
(15.07%) 
0 
(0.00%) 
0   
(0.00%) 
0  
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
33 
(20.00%) 
0 
(0.00%) 
0   
(0.00%) 
45 (15.25%) 
GOS30d            251 (26.73%) 
1 0 
(0.00%) 
0 
(0.00%) 
10 
(16.67%) 
0 
(0.00%) 
0   
(0.00%) 
14 
(12.61%) 
2  
(5.26%) 
0 
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
0  
(0.00%) 
26 (10.36) 
2 0 
(0.00%) 
0 
(0.00%) 
1  
(1.67%) 
1 
(2.38%) 
0   
(0.00%) 
3  
(2.70%) 
0  
(0.00%) 
0 
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
0  
(0.00%) 
5 (1.99%) 
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3 0 
(0.00%) 
0 
(0.00%) 
42 
(70.00%) 
6 
(14.29%) 
0   
(0.00%) 
13 
(11.71%) 
11 
(28.95%) 
0 
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
0  
(0.00%) 
72 (28.69%) 
4 0 
()0.00% 
0 
(0.00%) 
4  
(6.67%) 
8 
(19.05%) 
0   
(0.00%) 
35 
(31.53%) 
7 
(18.42%) 
0 
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
0  
(0.00%) 
54 (21.51%) 
5 0 
(0.00%) 
0 
(0.00%) 
3  
(5.00%) 
27 
(64.29%) 
0   
(0.00%) 
46 
(41.44%) 
18 
(47.37%) 
0 
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
0  
(0.00%) 
94 (37.45%) 
GOS3m            356 (37.91%) 
1 0 
(0.00%) 
0 
(0.00%) 
10 
(17.24%) 
0 
(0.00%) 
0   
(0.00%) 
2  
(3.45%) 
2  
(8.00%) 
0 
(0.00%) 
31 
(16.15%) 
0 
(0.00%) 
0  
(0.00%) 
45 (12.64%) 
2 0 
(0.00%) 
0 
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
0   
(0.00%) 
0  
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
2  
(1.04%) 
0 
(0.00%) 
0  
(0.00%) 
2 (0.56%) 
3 0 
(0.00%) 
0 
(0.00%) 
28 
(48.28%) 
3 
(13.04%) 
0   
(0.00%) 
4  
(6.90%) 
5 
(20.00%) 
0 
(0.00%) 
11 
(5.73%) 
0 
(0.00%) 
0  
(0.00%) 
51 (14.33%) 
4 0 
(0.00%) 
0 
(0.00%) 
9 
(15.52%) 
4 
(17.39%) 
0   
(0.00%) 
14 
(24.14%) 
8 
(32.00%) 
0 
(0.00%) 
55 
(28.65%) 
0 
(0.00%) 
0  
(0.00%) 
90 (25.28%) 
5 0 
(0.00%) 
0 
()0.00% 
11 
(18.97%) 
16 
(69.57%) 
0   
(0.00%) 
38 
(65.52%) 
10 
(40.00%) 
0 
(0.00%) 
93 
(48.44%) 
0 
(0.00%) 
0  
(0.00%) 
168 (47.19%) 
GOS6m            364 (38.76%) 
1 0 
(0.00%) 
0 
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
15 
(9.26%) 
0  
(0.00%) 
1 
(50.00%) 
0 
(0.00%) 
33 
(10.50%) 
0 
(0.00%) 
0  
(0.00%) 
49 (13.46%) 
2 2 
(6.06%) 
0 
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
0   
(0.00%) 
0  
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
0  
(0.00%) 
2 (0.55%) 
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3 3 
(9.09%) 
0 
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
19 
(11.73%) 
2 
(33.33%) 
1 
(50.00%) 
0 
(0.00%) 
3  
(1.86%) 
0 
(0.00%) 
0  
(0.00%) 
28 (7.69%) 
4 6 
(18.18%) 
0 
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
48 
(29.63%) 
2 
(33.33%) 
0  
(0.00%) 
0 
(0.00%) 
39 
(24.22%) 
0 
(0.00%) 
0  
(0.00%) 
95 (26.10%) 
5 22 
(66.67%) 
0 
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
80 
(49.38%) 
2 
(33.33%) 
0  
(0.00%) 
0 
(0.00%) 
86 
(53.42%) 
0 
(0.00%) 
0  
(0.00%) 
190 (52.20%) 
GOS1y            221 (23.54%) 
1 0 
(0.00%) 
0 
(0.00%) 
10 
(17.86%) 
0 
(0.00%) 
0   
(0.00%) 
0  
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
33 
(20.00%) 
0 
(0.00%) 
0  
(0.00%) 
43 (19.46%) 
2 0 
(0.00%) 
0 
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
0   
(0.00%) 
0  
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
0  
(0.00%) 
0 (0.00%) 
3 0 
(0.00%) 
0 
(0.00%) 
10 
(17.86%) 
0 
(0.00%) 
0   
(0.00%) 
0  
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
3  
(1.82%) 
0 
(0.00%) 
0  
(0.00%) 
13 (5.88%) 
4 0 
(0.00%) 
0 
(0.00%) 
8 
(14.29%) 
0 
(0.00%) 
0   
(0.00%) 
0  
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
33 
(20.00%) 
0 
(0.00%) 
0  
(0.00%) 
41 (18.55%) 
5 0 
(0.00%) 
0 
(0.00%) 
28 
(50.00%) 
0 
(0.00%) 
0   
(0.00%) 
0  
(0.00%) 
0  
(0.00%) 
0 
(0.00%) 
96 
(58.18%) 
0 
(0.00%) 
0  
(0.00%) 
124 (56.11%) 
DIND            566 (60.28%) 
No 29 
(78.38%) 
73 
(76.84%) 
61 
(70.93%) 
35 
(63.64%) 
0   
(0.00%) 
2 
(22.22%) 
34 
(77.27%) 
0 
(0.00%) 
89 
(45.35%) 
0 
(0.00%) 
40 
(83.33%) 
363 (64.13%) 
Yes 8 
(21.62%) 
22 
(23.16%) 
25 
(29.07%) 
20 
(36.36%) 
0   
(0.00%) 
7 
(77.78%) 
10 
(22.73%) 
0 
(0.00%) 
103 
(53.65%) 
0 
(0.00%) 
8 
(16.67%) 
203 (35.87%) 
33 
Table 2 continued 
Rad_inf            107 (11.40%) 
No 28 
(75.68%) 
80 
(84.21%) 
68 
(85.00%) 
38 
(69.09%) 
0   
(0.00%) 
0   
(0.00%) 
21 
(47.73%) 
0   
(0.00%) 
0   
(0.00%) 
0   
(0.00%) 
0   
(0.00%) 
61 (57.01%) 
Yes 9 
(24.32%) 
15 
(15.79%) 
12 
(15.00%) 
17 
(30.91%) 
0   
(0.00%) 
0   
(0.00%) 
23 
(52.27%) 
26 
(100.0%) 
0   
(0.00%) 
0   
(0.00%) 
0   
(0.00%) 
46 (42.99%) 
Angio_VS            504 (53.67%) 
No 0   
(0.00%) 
58 
(61.05%) 
22 
(37.29%) 
35 
(63.64%) 
0   
(0.00%) 
106 
(79.70%) 
1 
(14.29%) 
0   
(0.00%) 
60 
(53.10%) 
12 
(54.55%) 
13 
(65.00%) 
307 (60.91%) 
Yes 0   
(0.00%) 
37 
(38.95%) 
37 
(62.71%) 
20 
(36.36%) 
0   
(0.00%) 
27 
(20.30%) 
6 
(85.71%) 
0   
(0.00%) 
53 
(46.90%) 
10 
(45.45%) 
7 
(35.00%) 
197 (39.09) 
Def_VS            561 (59.74%) 
No 31 
(88.57%) 
0   
(0.00%) 
0   
(0.00%) 
29 
(70.73%) 
64 
(68.82%) 
67 
(50.38%) 
39 
(92.86%) 
27 
(79.41%) 
87 
(47.54%) 
0   
(0.00%) 
0   
(0.00%) 
344 (61.32%) 
Yes 4 
(11.43%) 
0   
(0.00%) 
0   
(0.00%) 
12 
(29.27%) 
28 
(31.18%) 
66 
(49.62%) 
3  
(7.14%) 
7 
(20.59%) 
96 
(52.46%) 
0   
(0.00%) 
0   
(0.00%) 
217 (38.68%) 
             
34 
3.1.3 Haptoglobin 
Hardy-Weinberg equilibrium of each study was assessed, and the detailed result of frequency 
and percentage were shown in Table 3. The chi2 were calculated by OEGE online calculator, and 
p-values were calculated at 1 degree of freedom.
35 
 
Table 3. Descriptive of Hp genotype 
 
Study A 
(n=37) 
Study B 
(n=95) 
Study C 
(n=86) 
Study D 
(n=55) 
Study E 
(n=169) 
Study F 
(n=143) 
Study G 
(n=46) 
Study H 
(n=37) 
Study I 
(n=192) 
Study J 
(n=30) 
Stud K 
(n=49) 
All 
(n=939) 
Hp1-1 
8 
(21.62%) 
7  
(7.37%) 
11 
(12.79%) 
13 
(23.64%) 
25 
(14.79%) 
34 
(23.78%) 
15 
(32.61%) 
6 
(16.22%) 
25 
(13.02%) 
9 
(30.00%) 
7 
(14.29%) 
160 
(17.04%) 
Hp2-1 
16 
(43.24%) 
39 
(41.05%) 
45 
(52.33%) 
30 
(54.55%) 
80 
(47.34%) 
62 
(43.36%) 
24 
(52.17%) 
22 
(59.46%) 
109 
(56.77%) 
10 
(33.33%) 
26 
(53.06%) 
463 
(49.31%) 
Hp2-2 
13 
(35.14%) 
49 
(51.58%) 
30 
(34.88%) 
12 
(21.82%) 
64 
(37.87%) 
47 
(32.87%) 
7 
(15.22%) 
9 
(24.32%) 
58 
(30.21%) 
11 
(36.67%) 
16 
(32.65%) 
316 
(33.65%) 
Chi-2 0.52 0.04 0.86 0.46 0 2.26 0.27 1.44 5.55 3.27 0.47  0.19 
p-value 0.471 0.841 0.354 0.498 1 0.133 0.603 0.230 0.018 0.071 0.493 0.663 
                     
36 
From Table 3  Hp in most studies had p-value larger than 0.05, which indicated they 
followed Hardy-Weinberg equilibrium and didn’t have ascertainment bias. However, in study I, 
the chi2 was 5.55 with p-value 0.018, which is much smaller than 0.05, and we can conclude that 
there was significant difference between observed and expected data. This bias may be caused by 
some other influences, such as gender, race, and something else. However, these are independent 
samples and the subjects are not related biologically.
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3.2 TWO-STAGE ANALYSIS 
The odds ratio was assessed, both unadjusted and adjusted. The unadjusted analysis calculated 
the odds ratio of clinical outcome between different groups of Hp without controlling any other 
covariates except time. The adjusted analysis was assessed while controlling core covariates and 
same additional covariates. 
The primary outcome was unfavorable outcome, defined as mRS 3-6 or GOS 1-3 when 
mRS were not available. All included 8 studies with primary outcome measure were mRS except 
for Study E with only GOS measure. Logistic regression model was used for Study E given only 
6 months measurement. Meta-Analysis of pooled odds ratio were calculated in STATA software 
(version 14.0 SE StataCorp, College Station, TX). 
3.2.1 Primary outcome (mRS and GOS)  
The point estimation, confidence interval and p-value of odds ratio are shown in Table 4 and 5, 
respectively. 
Table 4. The univariate association between Hp_variant (22 vs 11 & 21) and unfavorable outcome using GEE 
adjusting for time 
 
Study ID Sample size Time point OR 95% CI P-value 
A 
 
37 3,6 0.478 (0.116,1.963) 0.306 
B 
 
95 1,3,6 1.267 (0.577,2.785) 0.555 
C 
 
86 1,3 0.799 (0.340,1.878) 0.607 
D 
 
55 1,3,6 1.195 (0.242,5.914) 0.827 
38 
E 
 
169 6 0.909 (0.413, 2.00) 0.813 
F 
 
143 
 
1,3 0.725 (0.354,1.486) 0.380 
G 
 
46 1,3 2.244 (0.421,11.959) 0.344 
I 
 
192 3,6 1.549 (0.817,2.936) 0.180 
Meta-Analysis 
 
Pooled 1,3,6 1.035 (0.757,1.415) 0.828 
 
Table 4 above compared primary outcome in rare homozygotes (Hp-22) versus common 
homozygotes (Hp-11) and heterozygotes (Hp-21). From the Table 4, without adjusting any other 
covariates except time, all results were not significant, and we could conclude that there is no 
significant association between Hp and primary outcomes in any study group. Meta-analysis was 
used to assess the pooled odds ratio, and Figure 1 showed the result. 
  
• Heterogeneity chi-squared=5.18 (df=7) p=0.638 
• I-squared =0.0% 
• Estimate of between-study variance Tau-squared=0.0000 
• Figure 1. The pooled univariate association between Hp_variant (22 vs 11 & 21) and unfavorable outcome 
adjusting for time 
 
 
Meta-analysis of overall odds ratio indicated there were no significant difference between 
rare homozygotes versus common homozygotes and heterozygotes for primary outcomes, while 
Table 4 Continued 
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not controlling other covariates except time. The p-value of Q test indicated there was no 
significant heterogeneity (p=0.638) and I2 indicated no heterogeneity was observed (I2=0.00%). 
 
• Bias: t=-0.18 p=0.866 
Figure 2. Funnel plot of univariate association between Hp_variant (22 vs 11 & 21) and unfavorable outcome 
 
Figure 2 did not have asymmetry problems, which indicated there was no publication bias 
in this analysis. In the Egger test, no bias was observed with p-value larger than 0.05 (p=0.866). 
The adjusted analysis was calculated while controlling other covariates, and the 
covariates used are shown in Tables below. 
Table 5. The adjusted association between Hp_variant (22 vs 21 & 11) and unfavorable outcome using GEE 
Study ID covariate Sample size Time point OR 95% CI P-value 
A 
 
time HTN aneurysm 
treatment age 
WFNS fisher 
37 3,6 0.467 （0.085,2.571） 0.382 
B 
 
time HTN aneurysm 
treatment age 
WFNS 
95 1,3,6 1.001 (0.116,8.628) 0.999 
C 
 
time HTN aneurysm 
treatment age 
WFNS fisher 
85 1,3 0.695 (0.281,1.723) 0.433 
D 
 
time HTN aneurysm 
treatment age 
WFNS fisher 
42 1,3,6 1.017 (0.100,10.363) 0.988 
40 
E 
 
time HTN aneurysm 
treatment age 
WFNS fisher 
161 6 1.106 (0.450,2.722) 0.826 
F 
 
time HTN aneurysm 
treatment age 
WFNS fisher 
111 
 
1,3 0.672 (0.262,1.725) 0.409 
G 
 
time HTN aneurysm 
treatment age 
WFNS 
41 1,3 1.770 (0.338,9.279) 0.499 
I 
 
time HTN aneurysm 
treatment age 
WFNS fisher 
183 3,6 0.994 (0.454,2.177) 0.988 
Meta-
Analysis 
 
 Pooled 1,3,6 0.877 (0.589,1.306) 0.519 
 
Table 5 showed the point estimate, confidence interval and p-value of the association 
between Hp-22 versus Hp-11 and Hp-21. In analysis of all studies, covariates including time, 
HTN, aneurysm, treatment, age and WFNS were controlled. In Studies A, C, D, E, F, and I, 
Fisher Grade were also controlled in the GEE models. In Study B and G, because of the highly 
skewed distribution of Fisher Grade which leads to an un-estimable model, the Fisher Grade was 
not included in analysis of these studies. The results showed no significant association between 
Hp_variants and unfavorable outcome. The Figure of overall results for the Meta-Analyses 
follows. 
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• Heterogeneity Chi-squared=2.16 (df=7) p=0.951 
• I-squared = 0.0% 
• Estimate of between-study variance Tau-squared=0.0000 
Figure 3. The pooled adjusted association between Hp_variant (22 vs 21 & 11) and unfavorable outcome  
 
 Figure 3 above indicated there was no significant association between Hp_variant and 
unfavorable outcome while adjusting some other covariates, which is same as the conclusion of 
the analysis without controlling other covariates except time. Q test and I2 indicated there was no 
heterogeneity observed (p=0.951, I2=0.0%) 
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• Bias: t=0.18 p=0.865 
Figure 4. Funnel plot of adjusted association between Hp_variant (22 vs 11 & 21) and unfavorable outcome 
 
In Figure 4, the outer dashed lines indicate the triangular region within which 95% of 
studies were expected to lie in the absence of both biases and heterogeneity, and the solid 
vertical line corresponds to no intervention effect. This plot is symmetric, which indicates that 
there was no publication bias. The Egger test indicated there was no small-study effects, hence, 
that there was no publication bias problem. 
3.2.2 Sensitivity Analysis 
• Sliding Dichotomy 
The primary outcomes were ordinal outcomes, and sliding dichotomy was based on mRS and 
GOS. This study included Study A, B, C, D, E, F, G, and I, and covariates including age, 
treatment, WFNS, HTN, and fisher grade were used to adjust the result. We included 8 studies 
with primary outcome measure (mRS) and one study, Study E, with only GOS measure.  
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Table 6. The association between Hp_variant (22 vs 21 & 11) and unfavorable outcome using sliding dichotomy 
Study ID Sample size covariates Time point OR 95% CI P-value 
A 
 
37 treatment age 
fisher wfns 
3,6 0.198 (0.039,1.005) 0.051 
B 95 treatment age 
wfns 
1,3,6 2.633 (0.960,7.223) 0.060 
C 86 age treatment 
fisher wfns 
1,3 0.748 (0.294,1.907) 0.544 
D 43 age treatment 
fisher wfns 
1,3,6 empty   
E 161 age treatment 
fisher wifns 
6 1.219 (0.568,2.619) 0.611 
F 127 age treatment 
fisher wifns 
1,3 1.036 (0.380,2.824) 0.945 
G 42 age treatment 
wifns 
1,3 empty   
I 192 age treatment 
fisher wifns 
3,6 0.957 (0.409,2.241) 0.920 
Meta-
Analysis 
  pooled 1.017 (0.616,1.681) 0.946 
 
The odds ratio in Study D and G was not estimable by sliding dichotomy, and they were 
not included in further analysis. Table 6 indicated there was no effect of Hp variant was observed 
on unfavorable outcome. 
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• Heterogeneity Chi-squared = 1.94 (df=6) p=0.160 
• I-squared=37% 
• Estimate of between-study variance Tau-squared=0.1431 
Figure 5. The pooled association between Hp_variant (22 vs 21 & 11) and unfavorable outcome using sliding 
dichotomy 
 
Figure 5 above indicated the pooled sliding dichotomy odds ratio was not significant 
different from 1, and there was no significant association between Hp variant and mRS or GOS 
in meta-analysis. The Q test indicated no heterogeneity problem (p=0.160), and the I2 showed 
37% of the variability across studies was due to heterogeneity rather than chance. Although no 
significant heterogeneity was detected in Q test, the inconsistency was moderately large. 
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• Bias: t-1.37 p=0.243 
Figure 6. Funnel plot of association between Hp_variant (22 vs 11 & 21) and unfavorable outcome using 
sliding dichotomy 
 
In Figure 6, the funnel plot was symmetric, which indicates that there was no publication 
bias issue. The Egger test also concluded the funnel plot didn’t have asymmetric issue and there 
was no publication bias. 
 
• Proportional Odds Logistic Regression Model 
The primary outcome mRS and GOS are ordinal outcomes. Proportional odds logistic regression 
model was used to estimate the odds ratio for each of the possible cut points of the mRS and 
GOS. Study A, B, C, D, E, F, G, and I with primary outcome (mRS or GOS) were included in 
this analysis, controlling for time, HTN, treatment, age, fisher grade, and WFNS. We included 8 
studies with primary outcome measure (mRS) and one study, Study E, with only GOS measure. 
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Table 7. The association between Hp_variant (22 vs 11 & 21) and unfavorable outcome using proportional 
odds logistic regression model 
 
Study ID covariate Sample 
size 
Time point OR 95% CI P-value 
A 
 
time HTN 
treatment 
age fisher 
WFNS 
37 3,6 0.315 (0.073,1.354) 0.120 
B 
 
Time HTN 
treatment 
age WFNS 
95 1,3,6 0.988 (0.448,2.181) 0.976 
C 
 
time HTN 
treatment 
age fisher 
WFNS 
86 1,3 0.799 (0.353,1.810) 0.591 
D 
 
time HTN 
treatment 
age fisher 
WFNS 
55 1,3,6 2.298 (0.527,10.020) 0.268 
E 
 
HTN 
treatment 
age fisher 
WFNS 
169 6 1.356 (0.721,2.550) 0.345 
F 
 
time HTN 
treatment 
age fisher 
WFNS 
143 
 
1,3 0.694 (0.353,1.365) 0.290 
G 
 
time HTN 
treatment 
age WFNS 
46 1,3 0.746 (0.203,2.744) 0.659 
I 
 
time HTN 
treatment 
age fisher 
WFNS 
192 3,6 0.823 (0.464,1.462) 0.507 
Meta-
Analysis 
  pooled 0.899 (0.676,1.195) 0.464 
 
 Table 7 above indicated there was no significant difference between the effect of 
different Hp variant (22 vs 11 & 21) on unfavorable outcome. 
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• Heterogeneity Chi-squared=6.04 (df=7) p=0.536 
• I-squared =0.0% 
• Estimate of between-study variance Tau-squared=0.0000 
Figure 7. The pooled association between Hp_variant (22 vs 11 & 21) and unfavorable outcome using 
proportional odds logistic regression model 
 
 Figure 7 above showed the common odds ratio using proportional odds logistic model as 
not significant different from 1, which indicated there was no significant effect of Hp variant on 
unfavorable outcome. In the heterogeneity test, both Q test and result of I2 indicated no 
heterogeneity was observed.  
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• Bias: t=-0.30 p=0.775 
Figure 8. Funnel plot of association between Hp_variant (22 vs 11 & 21) and unfavorable outcome using 
proportional odds logistic regression model 
 
Figure 8 and the t-statistics of Egger test indicated there was no publication bias in this 
meta-analysis because the funnel plot was not asymmetric (p=0.775). 
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3.2.3 Secondary Outcome (DIND, Rad_inf, Angio_VS and Def_VS) 
Secondary outcomes including DIND, Rad_inf (radiographic evidence of infarction), Angio_VS 
(Angiographic evidence of vasospasm), Def_VS (definite vasospasm/TCD evidence of 
vasospasm) were binary outcomes. Logistic regression models were conducted to look at 
connections between Hp genotype and outcomes. Models for the secondary outcomes were 
adjusted and unadjusted. 
• DIND 
Study A, B, C, D, G, and I contained information for DIND, and the analysis was based on these 
studies. 
 
Table 8. The univariate association between Hp_variant (22 vs 11 & 21) and DIND 
Study ID Sample 
size 
OR 95% CI P-value 
A 
 
37 0.545 (0.093,3.194) 0.501 
B 
 
95 2.458 (0.897,6.736) 0.080 
C 
 
86 1.367 (0.522,3.578) 0.525 
D 
 
55 0.844 (0.219,3.255) 0.805 
G 
 
44 1.45 (0.236,8.923) 0.689 
I 
 
192 1.335 (0.716,2.488) 0.364 
Meta-
analysis 
 1.258 (0.686,2.308) 0.458 
50 
 Table 8 indicated there were no significant association between Hp_variant (22 vs 11 & 
21) and DIND outcome with all p-value larger than 0.05 in all studies.  
 
• Heterogeneity Chi-squared=2.30 (df=5) p=0.806 
• I-squared=0.0% 
• Estimate of between-study variance Tau-squared=0.0000 
Figure 9. The pooled univariate association between Hp_variant (22 vs 11 & 21) and DIND 
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The result of Meta-Analysis above in Figure 9 indicated no effect of Hp_variant on 
DIND was observed (p-value=0.145). Q test indicated there was no heterogeneity problem, and 
I2 showed the same conclusion. 
 
• Bias: t=-0.77 t=0.485 
Figure 10. Funnel plot of univariate association between Hp_variant (22 vs 11 & 21) and DIND 
 
Figure 10 was symmetric which indicated there was no publication bias problem. The p-
value of bias in Egger test was 0.485 which confirmed the conclusion from the plot. 
The adjusted logistic regression model was used, and the result was as follows. 
 
Table 9. The adjusted association between Hp_variant (22 vs 11 & 21) and DIND  
Study ID covariates Sample size OR 95% CI P-value 
A 
 
Age WFNS Treatment HTN 37 0.455 (0.070,2.947) 0.409 
B 
 
Age WFNS Treatment HTN 95 2.201 (0.772,6.274) 0.140 
C 
 
Age WFNS Treatment HTN 84 1.556 (0.551,4.395) 0.404 
D 
 
Age WFNS Treatment HTN Fisher 55 0.690 (0.146,3.263) 0.640 
F Age 9 1.566 (0.062,39.515) 0.786 
G 
 
Age WFNS Treatment HTN 43 1.788 (0.248,12.884) 0.564 
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I 
 
Age WFNS Treatment HTN Fisher 183 0.907 (0.430,1.912) 0.797 
K Age Treatment HTN Fisher 24 0.393 (0.027,5.584) 0.490 
Meta-
Analysis 
  1.141 (0.724,1.798) 0.571 
 
Table 9 indicated there was no effect of Hp variant (22 vs 11 & 21) on DIND outcome 
while controlling for other covariates, including age, WFNS, treatment, HTN, and fisher grade. 
For Study F, only age was the only covariate being adjusted. 
 
• Heterogeneity Chi-squared=4.40 (df=7) p=0.733 
• I-squared=0.0% 
• Estimate of between-study variance Tau-squared=0.0000 
Figure 11. The pooled adjusted association between Hp_variant (22 vs 11 & 21) and DIND  
 
 Figure 11 indicated the odds ratio from the pooled logistic regression analysis on Hp 
variant and DIND outcome was not significant different from 1, which indicated DIND didn’t 
change in different Hp variant. Both Q test in I2 indicated no heterogeneity issue in this meta-
analysis and the result was consistent. 
Table 9 Continued 
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• Bias: t=-0.53 p=0.618 
Figure 12. Funnel plot of adjusted association between Hp_variant (22 vs 11 & 21) and DIND 
 
Figure 12 didn’t show asymmetric and there was no publication bias issue. In the test of 
asymmetric in funnel plot, Egger test showed there was asymmetric issue which indicated no 
small-study effects was observed.  
• Rad_inf 
Study A, B, C, D, and G had information of Rad_inf, and they were included in this analysis. 
Table 10. The univariate association between Hp_variant (22 vs 11 & 21) and Rad_inf 
Study ID Sample 
size 
OR 95% CI P-value 
A 
 
37 0.900 (0.184,4.400) 0.896 
B 
 
95 2.103 (0.659,6.704) 0.209 
C 
 
80 0.652 (0.161,2.644) 0.550 
D 
 
54 1.25 (0316,4.940) 0.750 
G 
 
44 1.26 (0.248,6.446) 0.779 
Meta-
Analysis 
 1.215 (0.650,2.270) 0.542 
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 Table 10 above indicated no significant effect of Hp variant (22 vs 11 & 21) on Rad_inf 
outcome was observed. 
 
• Heterogeneity Chi-squared=1.76 (df=4) p=0.780 
• I-squared=0.0% 
• Estimate of between-study variance Tau-squared=0.0000 
Figure 13. The pooled univariate association between Hp_variant (22 vs 11 & 21) and Rad_inf 
 
 Figure 13 showed the pooled odds ratio of Rad_inf in Hp-22 versus Hp-11 and Hp-21. 
The result indicated there was not significant association between Hp_variant and Rad_inf. 
Large p-value of Q test (p=0.780) and value of I2 indicated no heterogeneity was observed in this 
study. 
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• Bias: t=-1.39 p=0.259 
Figure 14. Funnel plot of univariate association between Hp_variant (22 vs 11 & 21) and Rad_inf 
 
Plot in Figure 14 looked symmetric, and Egger test didn’t show asymmetric issue, which 
indicated was no publication bias problem. 
 The results while controlling other covariates follows. 
 
Table 11. The adjusted association between Hp_variant (22 vs 11 & 21) and Rad_inf  
Study ID Covariate Sample size OR 95% CI P-value 
A 
 
Aneurysm Age WFNS Treatment 
HTN 
37 1.027 (0.176,6.013) 0.976 
B 
 
Aneurysm Age WFNS Treatment 
HTN  
95 1.934 (0.573,6.533) 0.288 
C 
 
Aneurysm Age WFNS Treatment 
HTN  
79 0.832 (0.183,3.773) 0.812 
D 
 
Aneurysm Age WFNS Treatment 
HTN   Fisher 
54 1.390 (0.296,6.535) 0.677 
G 
 
Aneurysm Age WFNS Treatment 
HTN Fisher 
43 0.905 (0.136,5.999) 0.917 
Meta_Analysis   1.255 (0.632,2.490) 0.516 
 
 After controlling other covariates (aneurysm, age, WFNS, treatment, HTN, and fisher 
grade in some studies), as Table 11 showed above, the point estimate was different, but p-value 
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are all larger than 0.05, indicating there was no significant association between Hp_variant (22 
vs 11 & 21) and Rad_inf. 
 
• Heterogeneity Chi-squared=0.95 (df=4) p=0.917 
• I-squared=0.0% 
• Estimate of between-study variance Tau-squared=0.0000 
Figure 15. The pooled adjusted association between Hp_variant (22 vs 11 & 21) and Rad_inf  
 
Figure 15 indicated there was no effect of Hp_variant (22 vs 11 & 21) on Rad_inf was 
observed while controlling other covariates. In the test of heterogeneity, both Q test and I2 
indicated there was no heterogeneity, and the result of analysis was consistent.  
57 
 
• Bias: t=-2.2 p=0.115 
Figure 16. Funnel plot of adjusted association between Hp_variant (22 vs 11 & 21) and Rad_inf 
 
Figure 16 indicated the two-stage adjusted analysis of association between Hp genotype 
and Rad_inf didn’t have publication bias (p=0.115). 
The adjusted analysis had different result from unadjusted one after controlling for other 
covariates. However, they all had the same conclusion that Hp variant did not have a significant 
effect on Rad_inf outcome. 
• Def_VS 
Analysis of Def_VS was based on Study A, D, E, F, G, H, and I. This analysis consisted two 
parts: unadjusted and adjusted. The results were as following.  
Table 12. The univariate association between Hp_variant (22 vs 11 & 21) and Def_VS 
Study ID Sample size OR 95% CI P-value 
A 
 
35 0.606 (0.056,6.547) 0.680 
D 
 
41 0.767 (0.131,4.475) 0.768 
E 
 
93 0.702 (0.276,1.785) 0.457 
F 
 
133 0.958 (0.471,1.952) 0.907 
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G 
 
42 3.4 (0.258,44.758) 0.352 
H 
 
34 0.396 (0.041,3.841) 0.424 
I 
 
183 0.783 (0.414,1.479) 0.450 
Meta-Analysis  0.822 (0.554,1.219) 0.329 
 
Table 12 above indicated there were no significant association between Hp_variant (22 vs 
11 & 21) and Def_VS with p-value in all studies were larger than 0.05. 
 
 
• Heterogeneity Chi-squared-1.94 (df=6) p=0.925 
• I-squared=0.0% 
• Estimate of between-study variance Tau-squared=0.0000 
Figure 17. The pooled univariate association between Hp_variant (22 vs 11 & 21) and Def_VS 
 
Figure 17 indicated the univariate association between Hp_variant and Def_VS was not 
significant, and the pooled odds ratio was close to 1 (p-value=0.329). Q test and I2 indicated no 
variability between studies that cannot be explained by chance (I2=0.0%). 
Table 12 Continued 
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• Bias: t=0.08 p=0.936 
Figure 18. Funnel plot of univariate association between Hp_variant (22 vs 11 & 21) and Def_VS 
 
Figure 18 and test statistic of Egger test indicated there was no publication bias since the 
plot was symmetric (p=0.936). 
The adjusted analysis of Def_VS was also done in these studies. However, controlling for 
all covariates in the modelling had problems including no convergence. In most studies, we 
controlled for age, WFNS, treatment, and fisher grade, but for Study A we only adjusted for 
HTN and age, for Study G we only adjusted for age, HTN and WFNS, and for Study H we 
controlled for age only. 
Table 13. The adjusted association between Hp_variant (22 vs 11 & 21) and Def_VS  
Study ID Covariate  Sample size OR 95% CI P-value 
A 
 
HTN Age 35 0.463 (0.041,5.279) 0.535 
D 
 
Age WFNS Treatment HTN Fisher 41 0.978 (0.125,7.619) 0.983 
E 
 
Age WFNS Treatment HTN Fisher 93 0.715 (0.256,2.000) 0.523 
F 
 
Age WFNS Treatment HT Fisher 116 0.669 (0.270,1.657) 0.385 
G 
 
Age HTN WFNS 41 4.518 (0.237,85.951) 0.316 
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H Age 34 0.454 (0.040,5.139) 0.524 
I 
 
Age WFNS Treatment HT Fisher 174 1.079 (0.525,2.218) 0.836 
Meta-
Analysis 
  0.854 (0.540,1.349) 0.498 
 
Table 13 above indicated there were no significant effect of Hp variant on Def_VS 
outcome with p-value in all group were larger than 0.05. The range of 95% confidence interval in 
Study G was quite wide (0.237, 85.951), so further analysis with more observation was needed.    
 
 
• Heterogeneity Chi-squared=2.55 (df=6) p=0.863 
• I-squared=0.0% 
• Estimate of between-study variance Tau-squared=0.0000 
Figure 19. The pooled adjusted association between Hp_variant (22 vs 11 & 21) and Def_VS  
 
In the result of Meta-analysis in Figure 19, Study I had the heaviest weight, and the 
conclusion was no significant association between Hp_variant and Def_VS at level 0.05. Both Q 
test and I2 indicated chance could explain all variability between studies as p-value larger than 
0.05 and 0.0% I2. 
Table 13 Continued 
61 
 
• Bias: t=0.01 p=0.995 
Figure 20. Funnel plot of adjusted association between Hp_variant (22 vs 11 & 21) and Def_VS 
 
Plot in Figure 20 indicated there was no publication bias since no asymmetric issue was 
observed (p=0.995). 
The conclusion of adjusted analysis was same as unadjusted one, even though they had 
different results. 
• Angio_VS 
The analysis on Angio_VS outcome was based on Study B, C, D, F, I, J, and K. The sample size 
of Study J and K were quite small. The unadjusted and adjusted were used in this analysis, and 
the results were as follows. 
 
Table 14. The univariate association between Hp_variant (22 vs 11 & 21) and Angio_VS 
Study ID Sample 
size 
OR 95% CI P-value 
B 
 
95 3.597 (1.492,8.668) 0.004 
C 
 
59 1.623 (0.514,5.125) 0.409 
D 
 
55 0.844 (0.219,3.255) 0.805 
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F 
 
133 1.097 (0.456,2.638) 0.836 
I 
 
113 0.620 (0.277,1.387) 0.245 
J 
 
22 2 (0.324,12.329) 0.455 
K 
 
20 1.333 (0.165,10.743) 0.787 
Meta-
Anlysis 
 1.329 (0.778,2.271) 0.298 
 
Table 14 above showed the unadjusted association between Hp_variant and Angio_VS 
outcome. Most p-value were larger than 0.05, and the null hypothesis that there was no 
association was not rejected in any study. However, the p-value of Study B was less than 0.05, 
which indicated Hp-22 genotype imparted a better Angio_VS outcome compared to Hp-11 and 
Hp-21 (OR=3.597, 95% CI (1.492,8.668), p=0.004). 
 
• Heterogeneity Chi-squared=9.28 (df=6) p=0.158 
• I-squared=35.4% 
• Estimate of between-study variance Tau-squared=0.1767 
Figure 21. The pooled univariate association between Hp_variant (22 vs 11 &21) and Angio_VS 
 
Table 14 Continued 
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Although the odds ratio of Study B was larger than 1, the pooled odds ratio from Figure 
21 was still not significantly different from 1, which indicated there was not association between 
Hp_variant and Angio_VS outcome. In the test of heterogeneity, Q test indicated the 
heterogeneity is not significant, but I2 is 35.4% and it was moderately large. 
 
 
• Bias: t=0.26 p=0.804 
Figure 22. Funnel plot of univariate association between Hp_variant (22 vs 11 & 21) and Angio_VS 
 
Although there was one outlier in funnel plot in Figure 22, there were no publication bias 
issue since the plot was symmetric (p=0.804). 
In the adjusted analysis, covariates including age, WFNS, treatment, HTN and fisher 
grade were used except study I and K. 
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Table 15. The adjusted association between Hp_variant (22 vs 11 & 21) and Angio_VS  
Study ID Covariate Sample size OR 95% CI P-value 
B 
 
Age WFNS 
Treatment 
HTN Fisher 
94 3.268 (1.293,8.262) 0.012 
C 
 
Age WFNS 
Treatment 
HTN Fisher 
59 2.203 (0.612,7.936) 0.227 
D 
 
Age WFNS 
Treatment 
HTN Fisher 
55 0.690 (0.146,3.263) 0.640 
F 
 
Age WFNS 
Treatment 
HTN Fisher 
116 0.776 (0.265,2.273) 0.643 
I 
 
Age WFNS 
Treatment 
HTN Fisher 
107 0.452 (0.182,1.122) 0.087 
J 
 
Age Treatment 
HTN 
22 1.834 (0.221,15.176) 0.574 
K 
 
Age Treatment 
HTN 
20 0.453 (0.033,6.294) 0.556 
Meta-
Analysis 
  1.125 (0.707,1.791) 0.619 
 
In Table 15, after controlling for covariates, Hp-22 genotype in Study B still had 
significant higher probability to have Angio_VS (p=0.012). 
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• Heterogeneity Chi-squared=11.50 (df=6) p=0.074 
• I-squared=47.8% 
• Estimate of between-study variance Tau-squared=0.3844 
Figure 23. The pooled adjusted association between Hp_variant (22 vs 11 &21) and Angio_VS  
 
From Figure 23 above, although the odds ratio of Study B was significantly different 
from 1, the pooled effect of Hp variant on Angio_VS was not observed. There is no significant 
heterogeneity in Q test (p=0.074), but I2 showed that majority of the variability across studies 
were because of heterogeneity, and the inconsistency was moderately large (I2=47.8%) 
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• Bias: t=-0.16 p=0.882 
Figure 24. Funnel plot of adjusted association between Hp_variant (22 vs 11 & 21) and Angio_VS 
 
There was one outlier in Figure 24 which needed to be considered, but the plot is 
symmetric and there was no publication bias (p=0.882). 
3.3 ONE-STAGE ANALYSIS 
One-stage analysis was used for both primary and secondary outcomes. In the primary outcome, 
study site and time were considered as random effect. In the secondary outcome, study site was 
considered as random effect. The comparison of result in two-stage and one-stage analysis is as 
following. 
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Table 16. The univariate association between Hp_variant (22 vs 21 & 11) and outcome summary 
Outcome Two-Stage 
(OR 
95% CI 
p-value) 
One-Stage 
(OR 
95% CI 
p-value) 
mRS & GOS 1.035 
(0.757,1.415) 
0.828 
1.322 
(0.443,3.964) 
0.617 
DIND 1.361 
(0.889,2.061) 
0.145 
1.305 
(0.887,1.920) 
0.177 
Rad_inf 1.215 
(0.650,2.270) 
0.542 
1.193 
(0.656,2.171) 
0.563 
Angio_VS 1.304 
(0.886,1.964) 
0.203 
1.297 
(0.874,1.923) 
0.196 
Def_VS 0.822 
(0.554,1.219) 
0.329 
0.822 
(0.556,1.216) 
0.327 
 
 
Table 16 above indicated the result of univariate association in two-stage and one-stage 
analysis in primary outcome had some difference but the results for secondary outcome were 
quite similar with each other. The difference in primary outcome may because of different 
methods. The GEE method was used in first step of two-stage analysis, and mixed effect logistic 
model was used in one-stage analysis. Both analyses had the same conclusion of no pooled effect 
of Hp on outcome after aSAH was observed. 
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Table 17. The adjusted association between Hp_variant (22 vs 21 & 11) and outcome summary  
Outcome covariates Two-Stage 
(OR 
95% CI 
p-value) 
One-Stage 
(OR 
95% CI 
p-value) 
mRS&GOS Age WFNS 
Treatment 
Time 
0.877 
(0.589,1.306) 
0.519 
1.180 
(0.387,3.601) 
0.771 
DIND Age WFNS 
HTN 
Treatment 
1.141 
(0.724,1.798) 
0.571 
1.324 
(0.872,2.010) 
0.199 
Rad_inf Age WFNS 
HTN 
Treatment 
1.225 
(0.632,2.490) 
0.516 
1.110 
(0.604,2.043) 
0.736 
Angio_VS Age WFNS 
HTN 
Treatment 
1.125 
(0.707,1.791) 
0.619 
1.249 
(0.811,1.923) 
0.312 
Def_VS Age WFNS 
HTN 
Treatment 
0.854 
(0.540,1.349) 
0.498 
0.901 
(0.583,1.392) 
0.638 
 
In Table 17, the difference between two-stage and one-stage analysis while controlling 
for other covariates was more than unadjusted analysis, which may be caused by the covariates 
being used in the adjusted models. Meanwhile, these two analyses drew the same conclusion that 
there was no significant association between Hp variant and outcome. 
69 
4.0  DISCUSSION AND CONCLUSION 
Individual level Meta-analyses on the inconsistent findings from the current literature for the 
association between Hp and aSAH recovering are lacking, and most previous research focused 
on one outcome.  
The primary outcomes (mRS and GOS) were measured repeatedly up to 6 months. The 
outcome measure of the same subject at different time points are correlated, hence GEE method 
with logistic regression model was used to account for the correlation between different time 
measurements within the same subject. The odds ratio in each study and the pooled odds ratio 
across all studies, which were obtained from meta-analysis, indicated there was no association 
between Hp genotype and unfavorable outcome. 
Secondary outcome analysis was a cross sectional study based on four different 
outcomes. Without the effect of time on each subject, logistic regression model was used in each 
outcome of each study. Although in some studies different Hp genotype had different effect on 
some outcomes, the pooled odds ratio still indicated no relationship between Hp and secondary 
outcomes. 
Sliding dichotomy and proportional odds logistic regression are two alternative models to 
avoid losing information about outcome and reducing statistical power of mRS and GOS. Using 
these two models in an ordinal outcome is more accurate and precise rather than simply 
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dichotomizing. The Meta-analysis still indicated there was no pooled association between Hp 
genotype and unfavorable outcome. 
In the two-stage analysis, logistic regression model was used in the first step to estimate 
the odds ratio in each study on both primary and secondary outcomes. The GEE method was 
conducted for primary outcomes because of the repeated measurements. With different effect 
sizes, a meta-analysis with random effect model was conducted in the second step. For some 
outcomes in the first step analysis, the odds ratio and p-value indicated there was an effect of Hp 
genotype on outcome, but there was no significant association after combing all studies by meta-
analysis. In the test of heterogeneity in meta-analysis, all studies showed there was no 
heterogeneity in Q test, but I2 in some studies indicated majority of the variability across studies 
were due to heterogeneity instead of chance, and the inconsistency was moderately large. Large 
I2 in these studies may be due to lack of power with a small number of studies (less than 10 
studies). The I2 estimate’s dependence on power, trial weights and time-lag bias, and these 
factors may cause fluctuation beyond the play of chance. Reporting 95% confidence interval 
should be more appropriate to assess the degree of heterogeneity. The funnel plot was used to 
access the publication bias in meta-analysis, and all plots were symmetric and there was no 
publication bias. Also, Egger test generated the same conclusion that all funnel didn’t have 
asymmetric problem. 
In one-stage analysis, all data were fitted in mixed effect logistic regression model, and 
each study was considered as a cluster. For primary outcomes, each individual subject was also 
considered as a cluster because of repeated measurement over time. Results for the secondary 
outcome analysis was quite similar as the two-stage analysis, but there were some differences 
between two approaches for the primary outcome. There are few reasons for this difference. 
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Firstly, the GEE method was used in first step of the two-stage analysis, but the one-stage 
analysis used a mixed model, different methods with different equations may lead to different 
results. Second, each study had a different weight in the meta-analysis and the mixed model, 
which is another reason for this difference. 
In the analyses of Hp and primary outcome at each time point, there were some 
significant associations between Hp and aSAH in some studies, but the pooled odds ratio from 
meta-analysis still indicated a negative relationship.  
The sample size in each study was relatively small, and the subjects were mainly 
white/caucasian. This limits the generalization of the results. The Hp genotype/allele frequencies 
in Study I weren’t in Hardy-Weinberg equilibrium. Interactions of covariates in this study could 
be considered in the model to have a more accurate estimation. GOS and mRS are long-term 
outcome measures after aSAH, so extending study period with more time points will provide a  
more appropriate estimate. Analyzing some other, more detailed outcomes of aSAH recovery is 
another way to assess the relationship between Hp genotype and aSAH. 
In summary negative findings were ascertained for the association between Hp genotype 
and outcome after aSAH from meta-analysis. However, given the limited number and small 
sample size of the studies included, the association needs to be evaluated further with more 
large-scaled prospective studies. 
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APPENDIX A: RELEVANT STATA CODES (mRS) 
Import excel "D:\pitt\study\Project-Meta\part 2\IPLD_coded_combined_ANALYSIS_pitt_08011 
7 (1).xlsx", sheet("Data") firstrow allstring clear 
*transfer mRS to two results, 1 for favorable, 0 for unfavorable 
gen m1=. 
replace m1=0 if mRS30d=="0" 
replace m1=0 if mRS30d=="1" 
replace m1=0 if mRS30d=="2" 
replace m1=1 if mRS30d=="3" 
replace m1=1 if mRS30d=="4" 
replace m1=1 if mRS30d=="5" 
replace m1=1 if mRS30d=="6" 
gen m2=. 
replace m2=0 if mRS3m=="0" 
replace m2=0 if mRS3m=="1" 
replace m2=0 if mRS3m=="2" 
replace m2=1 if mRS3m=="3" 
replace m2=1 if mRS3m=="4" 
replace m2=1 if mRS3m=="5" 
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replace m2=1 if mRS3m=="6" 
gen m3=. 
replace m3=0 if mRS6m=="0" 
replace m3=0 if mRS6m=="1" 
replace m3=0 if mRS6m=="2" 
replace m3=1 if mRS6m=="3" 
replace m3=1 if mRS6m=="4" 
replace m3=1 if mRS6m=="5" 
replace m3=1 if mRS6m=="6" 
 
 
*generate obs for data 
gen obs=_n 
 
*transfer data from wide to long (longitudinal) 
reshape long m, i(obs) j(time) 
 
 
*transfer time as 1, 3, 6 months (time2 as core covariate) 
gen time2=. 
replace time2=1 if time==1 
replace time2=3 if time==2 
replace time2=6 if time==3 
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*transfer Age, Treatment, WFNS, Fisher, Hp from string to numeric data 
destring Age, gen(age) 
destring Treatment, gen(treatment) 
destring WFNS, gen(wfns) 
destring Fisher, gen(fisher) 
gen hpp=. 
replace hpp=0 if Hp=="1" 
replace hpp=0 if Hp=="2" 
replace hpp=1 if Hp=="3" 
 
*don't analysis 6 month in Study F and G  
drop if Study_ID=="F" & time2==6 
drop if Study_ID=="G" & time2==6 
drop if treatment==3 
 
*mRS unadjusted 
xtgee m i.hpp i.time if Study_ID =="A"&(time2==3|time2==6), family(b) link(logit) corr(exch) 
i(obs) t(time2) robust eform 
xtgee m i.hpp i.time if Study_ID =="B", family(b) link(logit) corr(exch) i(obs) t(time2) robust 
eform 
xtgee m i.hpp i.time if Study_ID =="C"&(time2==1|time2==3), family(b) link(logit) corr(exch) 
i(obs) t(time2) robust eform 
75 
xtgee m i.hpp i.time if Study_ID =="D", family(b) link(logit) corr(exch) i(obs) t(time2) robust 
eform 
xtgee m i.hpp i.time if Study_ID =="F"&(time2==1|time2==3), family(b) link(logit) corr(exch) 
i(obs) t(time2) robust eform 
xtgee m i.hpp i.time if Study_ID =="G"&(time2==1|time2==3), family(b) link(logit) corr(exch) 
i(obs) t(time2) robust eform 
xtgee m i.hpp i.time if Study_ID =="I"&(time2==3|time2==6), family(b) link(logit) corr(exch) 
i(obs) t(time2) robust eform 
 
*change treatment and do GEE with covariates 
gen treatment1=. 
replace treatment1=1 if treatment==1 
replace treatment1=2 if treatment==2 
gen diabetes=. 
replace diabetes=1 if Diabetes=="1" 
replace diabetes=0 if Diabetes=="0" 
destring HTN,gen( htn ) 
destring Aneurysm,gen(aneurysm) 
destring Race, gen(race) 
 
gen a1=. 
replace a1=0 if aneurysm ==1 
replace a1=0 if aneurysm ==2 
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replace a1=0 if aneurysm ==3 
replace a1=1 if aneurysm ==4 
 
xtgee m i.hpp i.time htn i.treatment1 age i.wfns i.fisher if Study_ID 
=="A"&(time2==3|time2==6), family(b) link(logit) corr(exch) i(obs) t(time2) robust eform 
nolog 
xtgee m i.hpp i.time htn i.treatment1 age i.wfns if Study_ID =="B", family(b) link(logit) 
corr(exch) i(obs) t(time2) robust eform nolog 
xtgee m i.hpp i.time htn i.treatment1 age i.wfns i.fisher if Study_ID 
=="C"&(time2==1|time2==3), family(b) link(logit) corr(exch) i(obs) t(time2) robust eform 
nolog 
xtgee m i.hpp i.time htn i.treatment1 age i.wfns i.fisher if Study_ID =="D", family(b) link(logit) 
corr(exch) i(obs) t(time2) robust eform nolog 
xtgee m i.hpp i.time htn i.treatment1 age i.wfns i.fisher if Study_ID 
=="F"&(time2==1|time2==3), family(b) link(logit) corr(exch) i(obs) t(time2) robust eform nolog 
xtgee m i.hpp i.time htn i.treatment1 age i.wfns if Study_ID =="G"&(time2==1|time2==3), 
family(b) link(logit) corr(exch) i(obs) t(time2) robust eform nolog 
xtgee m i.hpp i.time htn i.treatment1 age i.wfns i.fisher if Study_ID 
=="I"&(time2==3|time2==6), family(b) link(logit) corr(exch) i(obs) t(time2) robust eform nolog 
 
**sliding dichotomy 
**study A 
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xtgee m i.time i.treatment1 i.a1 i.htn age i.fisher i.wfns if Study_ID 
=="A"&(time2==3|time2==6), family(b) link(logit) corr(exch) i(obs) t(time2) robust eform 
predict phatA if Study_ID=="A" & (time2==3|time2==6) 
xtile phata=phatA, nquantiles(3) 
gen dichotomy=.  
replace dichotomy=1 if Study_ID=="A"&(time2==3|time2==6)&(m==1|m==0) 
replace dichotomy=0 if mRS3m=="0" & Study_ID=="A" & time2==3 
replace dichotomy=0 if mRS3m=="1" & Study_ID=="A" & time2==3 
replace dichotomy=0 if mRS3m=="2" & Study_ID=="A" & time2==3 
replace dichotomy=0 if mRS3m=="3" & Study_ID=="A" & time2==3 &(phata==2|phata==3) 
replace dichotomy=0 if mRS3m=="4" & Study_ID=="A" & time2==3 &phata==3 
replace dichotomy=0 if mRS6m=="0" & Study_ID=="A" & time2==6 
replace dichotomy=0 if mRS6m=="1" & Study_ID=="A" & time2==6 
replace dichotomy=0 if mRS6m=="2" & Study_ID=="A" & time2==6 
replace dichotomy=0 if mRS6m=="3" & Study_ID=="A" & time2==6 &(phata==2|phata==3) 
replace dichotomy=0 if mRS6m=="4" & Study_ID=="A" & time2==6 &phata==3 
****study A in overall 
xtgee dichotomy i.hpp time i.treatment1 age i.fisher i.wfns if Study_ID 
=="A"&(time2==3|time2==6), family(b) link(logit) corr(exch) i(obs) t(time2) robust eform 
**Study B 
xtgee m i.time diabetes htn a1 i.treatment1 age i.wfns if Study_ID =="B", family(b) link(logit) 
corr(exch) i(obs) t(time2) robust eform 
predict phatB if Study_ID=="B" 
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xtile phatb=phatB, nquantiles(3) 
replace dichotomy=1 if Study_ID=="B"&(m==1|m==0) 
replace dichotomy=0 if mRS3m=="0" & Study_ID=="B" & time2==3 
replace dichotomy=0 if mRS3m=="1" & Study_ID=="B" & time2==3 
replace dichotomy=0 if mRS3m=="2" & Study_ID=="B" & time2==3 
replace dichotomy=0 if mRS3m=="3" & Study_ID=="B" & time2==3 &(phatb==2|phatb==3) 
replace dichotomy=0 if mRS3m=="4" & Study_ID=="B" & time2==3 &phatb==3 
replace dichotomy=0 if mRS6m=="0" & Study_ID=="B" & time2==6 
replace dichotomy=0 if mRS6m=="1" & Study_ID=="B" & time2==6 
replace dichotomy=0 if mRS6m=="2" & Study_ID=="B" & time2==6 
replace dichotomy=0 if mRS6m=="3" & Study_ID=="B" & time2==6 &(phatb==2|phatb==3) 
replace dichotomy=0 if mRS6m=="4" & Study_ID=="B" & time2==6 &phatb==3 
replace dichotomy=0 if mRS30d=="0" & Study_ID=="B" & time2==1 
replace dichotomy=0 if mRS30d=="1" & Study_ID=="B" & time2==1 
replace dichotomy=0 if mRS30d=="2" & Study_ID=="B" & time2==1 
replace dichotomy=0 if mRS30d=="3" & Study_ID=="B" & time2==1 &(phatb==2|phatb==3) 
replace dichotomy=0 if mRS30d=="4" & Study_ID=="B" & time2==1 &phatb==3 
****study B overall 
xtgee dichotomy i.hpp i.time i.treatment1 age i.wfns if Study_ID =="B", family(b) link(logit) 
corr(exch) i(obs) t(time2) robust eform 
**study C 
xtgee m i.time diabetes htn a1 age i.treatment1 i.fisher i.wfns if Study_ID 
=="C"&(time2==1|time2==3), family(b) link(logit) corr(exch) i(obs) t(time2) robust eform 
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predict phatC if Study_ID=="C" & (time2==1|time2==3) 
xtile phatc=phatC, nquantiles(3) 
replace dichotomy=1 if Study_ID=="C"&(time2==3|time2==1)&(m==1|m==0) 
replace dichotomy=0 if mRS30d=="0" & Study_ID=="C" & time2==1 
replace dichotomy=0 if mRS30d=="1" & Study_ID=="C" & time2==1 
replace dichotomy=0 if mRS30d=="2" & Study_ID=="C" & time2==1 
replace dichotomy=0 if mRS30d=="3" & Study_ID=="C" & time2==1 &(phatc==2|phatc==3) 
replace dichotomy=0 if mRS30d=="4" & Study_ID=="C" & time2==1 &phatc==3 
replace dichotomy=0 if mRS3m=="0" & Study_ID=="C" & time2==3 
replace dichotomy=0 if mRS3m=="1" & Study_ID=="C" & time2==3 
replace dichotomy=0 if mRS3m=="2" & Study_ID=="C" & time2==3 
replace dichotomy=0 if mRS3m=="3" & Study_ID=="C" & time2==3 &(phatc==2|phatc==3) 
replace dichotomy=0 if mRS3m=="4" & Study_ID=="C" & time2==3 &phatc==3 
***study C overall 
xtgee dichotomy i.hpp i.time age i.treatment1 i.fisher i.wfns if Study_ID 
=="C"&(time2==1|time2==3), family(b) link(logit) corr(exch) i(obs) t(time2) robust eform 
**Study D 
xtgee m i.time diabetes htn i.treatment1 age i.fisher i.wfns if Study_ID =="D", family(b) 
link(logit) corr(exch) i(obs) t(time2) robust eform 
predict phatD if Study_ID=="D" 
xtile phatd=phatD, nquantiles(3) 
replace dichotomy=1 if Study_ID=="D"&(m==1|m==0) 
replace dichotomy=0 if mRS3m=="0" & Study_ID=="D" & time2==3 
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replace dichotomy=0 if mRS3m=="1" & Study_ID=="D" & time2==3 
replace dichotomy=0 if mRS3m=="2" & Study_ID=="D" & time2==3 
replace dichotomy=0 if mRS3m=="3" & Study_ID=="D" & time2==3 &(phatd==2|phatd==3) 
replace dichotomy=0 if mRS3m=="4" & Study_ID=="D" & time2==3 &phatd==3 
replace dichotomy=0 if mRS6m=="0" & Study_ID=="D" & time2==6 
replace dichotomy=0 if mRS6m=="1" & Study_ID=="D" & time2==6 
replace dichotomy=0 if mRS6m=="2" & Study_ID=="D" & time2==6 
replace dichotomy=0 if mRS6m=="3" & Study_ID=="D" & time2==6 &(phatd==2|phatd==3) 
replace dichotomy=0 if mRS6m=="4" & Study_ID=="D" & time2==6 &phatd==3 
replace dichotomy=0 if mRS30d=="0" & Study_ID=="D" & time2==1 
replace dichotomy=0 if mRS30d=="1" & Study_ID=="D" & time2==1 
replace dichotomy=0 if mRS30d=="2" & Study_ID=="D" & time2==1 
replace dichotomy=0 if mRS30d=="3" & Study_ID=="D" & time2==1 &(phatd==2|phatd==3) 
replace dichotomy=0 if mRS30d=="4" & Study_ID=="D" & time2==1 &phatd==3 
***study D overall 
xtgee dichotomy i.hpp i.time i.treatment1 age i.fisher i.wfns if Study_ID =="D", family(b) 
link(logit) corr(exch) i(obs) t(time2) robust eform 
**Study F 
xtgee m i.time diabetes htn a1 age i.treatment1 i.fisher i.wfns if Study_ID 
=="F"&(time2==1|time2==3), family(b) link(logit) corr(exch) i(obs) t(time2) robust eform 
predict phatF if Study_ID=="F" & (time2==1|time2==3) 
xtile phatf=phatF, nquantiles(3) 
replace dichotomy=1 if Study_ID=="F"&(time2==3|time2==1)&(m==1|m==0) 
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replace dichotomy=0 if mRS30d=="0" & Study_ID=="F" & time2==1 
replace dichotomy=0 if mRS30d=="1" & Study_ID=="F" & time2==1 
replace dichotomy=0 if mRS30d=="2" & Study_ID=="F" & time2==1 
replace dichotomy=0 if mRS30d=="3" & Study_ID=="F" & time2==1 &(phatf==2|phatf==3) 
replace dichotomy=0 if mRS30d=="4" & Study_ID=="F" & time2==1 &phatf==3 
replace dichotomy=0 if mRS3m=="0" & Study_ID=="F" & time2==3 
replace dichotomy=0 if mRS3m=="1" & Study_ID=="F" & time2==3 
replace dichotomy=0 if mRS3m=="2" & Study_ID=="F" & time2==3 
replace dichotomy=0 if mRS3m=="3" & Study_ID=="F" & time2==3 &(phatf==2|phatf==3) 
replace dichotomy=0 if mRS3m=="4" & Study_ID=="F" & time2==3 &phatf==3 
**study F overall 
xtgee dichotomy i.hpp i.time htn age i.treatment1 i.fisher i.wfns if Study_ID 
=="F"&(time2==1|time2==3), family(b) link(logit) corr(exch) i(obs) t(time2) robust eform 
**study G 
xtgee m i.time diabetes htn a1 i.treatment1 age i.wfns if Study_ID 
=="G"&(time2==1|time2==3), family(b) link(logit) corr(exch) i(obs) t(time2) robust eform 
predict phatG if Study_ID=="G" & (time2==1|time2==3) 
xtile phatg=phatG, nquantiles(3) 
replace dichotomy=1 if Study_ID=="G"&(time2==3|time2==1)&(m==1|m==0) 
replace dichotomy=0 if mRS30d=="0" & Study_ID=="G" & time2==1 
replace dichotomy=0 if mRS30d=="1" & Study_ID=="G" & time2==1 
replace dichotomy=0 if mRS30d=="2" & Study_ID=="G" & time2==1 
replace dichotomy=0 if mRS30d=="3" & Study_ID=="G" & time2==1 &(phatg==2|phatg==3) 
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replace dichotomy=0 if mRS30d=="4" & Study_ID=="G" & time2==1 &phatg==3 
replace dichotomy=0 if mRS3m=="0" & Study_ID=="G" & time2==3 
replace dichotomy=0 if mRS3m=="1" & Study_ID=="G" & time2==3 
replace dichotomy=0 if mRS3m=="2" & Study_ID=="G" & time2==3 
replace dichotomy=0 if mRS3m=="3" & Study_ID=="G" & time2==3 &(phatg==2|phatg==3) 
replace dichotomy=0 if mRS3m=="4" & Study_ID=="G" & time2==3 &phatg==3 
**study G overall 
xtgee dichotomy i.hpp i.time i.treatment1 htn age i.wfns if Study_ID 
=="G"&(time2==1|time2==3), family(b) link(logit) corr(exch) i(obs) t(time2) robust eform 
**study I 
xtgee m i.time diabetes htn a1 age i.treatment1 i.fisher i.wfns if Study_ID 
=="I"&(time2==3|time2==6), family(b) link(logit) corr(exch) i(obs) t(time2) robust eform 
predict phatI if Study_ID=="I" & (time2==3|time2==6) 
xtile phati=phatI, nquantiles(3) 
replace dichotomy=1 if Study_ID=="I"&(time2==3|time2==6)&(m==1|m==0) 
replace dichotomy=0 if mRS3m=="0" & Study_ID=="I" & time2==3 
replace dichotomy=0 if mRS3m=="1" & Study_ID=="I" & time2==3 
replace dichotomy=0 if mRS3m=="2" & Study_ID=="I" & time2==3 
replace dichotomy=0 if mRS3m=="3" & Study_ID=="I" & time2==3 &(phati==2|phati==3) 
replace dichotomy=0 if mRS3m=="4" & Study_ID=="I" & time2==3 &phati==3 
replace dichotomy=0 if mRS6m=="0" & Study_ID=="I" & time2==6 
replace dichotomy=0 if mRS6m=="1" & Study_ID=="I" & time2==6 
replace dichotomy=0 if mRS6m=="2" & Study_ID=="I" & time2==6 
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replace dichotomy=0 if mRS6m=="3" & Study_ID=="I" & time2==6 &(phati==2|phati==3) 
replace dichotomy=0 if mRS6m=="4" & Study_ID=="I" & time2==6 &phati==3 
**study I overall 
xtgee dichotomy i.hpp i.time htn age i.treatment1 i.fisher i.wfns if Study_ID 
=="I"&(time2==3|time2==6), family(b) link(logit) corr(exch) i(obs) t(time2) robust eform 
 
**oridinal 
***prepare 
gen om=. 
replace om=4 if mRS30d=="4" & time2==1 
replace om=4 if mRS30d=="5" & time2==1 
replace om=4 if mRS30d=="6" & time2==1 
replace om=3 if mRS30d=="3" & time2==1 
replace om=2 if mRS30d=="2" & time2==1 
replace om=1 if mRS30d=="1" & time2==1 
replace om=0 if mRS30d=="0" & time2==1 
 
replace om=4 if mRS3m=="4" & time2==3 
replace om=4 if mRS3m=="5" & time2==3 
replace om=4 if mRS3m=="6" & time2==3 
replace om=3 if mRS3m=="3" & time2==3 
replace om=2 if mRS3m=="2" & time2==3 
replace om=1 if mRS3m=="1" & time2==3 
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replace om=0 if mRS3m=="0" & time2==3 
 
replace om=4 if mRS6m=="4" & time2==6 
replace om=4 if mRS6m=="5" & time2==6 
replace om=4 if mRS6m=="6" & time2==6 
replace om=3 if mRS6m=="3" & time2==6 
replace om=2 if mRS6m=="2" & time2==6 
replace om=1 if mRS6m=="1" & time2==6 
replace om=0 if mRS6m=="0" & time2==6 
 
**study A 
ologit om i.hpp i.time htn i.treatment1 age i.fisher i.wfns if Study_ID 
=="A"&(time2==3|time2==6), cluster(obs) or 
**study B 
ologit om i.hpp i.time htn i.treatment1 age i.wfns if Study_ID =="B",cluster(obs) or 
**study C 
ologit om i.hpp i.time htn age i.treatment1 i.fisher i.wfns if Study_ID 
=="C"&(time2==1|time2==3),cluster(obs) or 
**study D 
ologit om i.hpp i.time htn i.treatment1 age i.fisher i.wfns if Study_ID =="D",cluster(obs) or 
**study F 
ologit om i.hpp i.time htn i.treatment1 age i.fisher i.wfns if Study_ID 
=="F"&(time2==1|time2==3),cluster(obs) or 
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**study G 
ologit om i.hpp i.time htn i.treatment1 age i.wfns if Study_ID 
=="G"&(time2==1|time2==3),cluster(obs) or 
**study I 
ologit om i.hpp i.time htn i.treatment1 age i.fisher i.wfns if Study_ID 
=="I"&(time2==3|time2==6),cluster(obs) or 
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APPENDIX B: RELEVANT STATA CODES (GOS) 
import excel "D:\pitt\study\Project-Meta\part 2\IPLD_coded_combined_ANALYSIS_pitt_080 
117 (1).xlsx", sheet("Data") firstrow allstring clear 
 
gen g1=. 
replace g1=0 if GOS30d=="4" 
replace g1=0 if GOS30d=="5" 
replace g1=1 if GOS30d=="1" 
replace g1=1 if GOS30d=="2" 
replace g1=1 if GOS30d=="3" 
gen g2=. 
replace g2=0 if GOS3m=="4" 
replace g2=0 if GOS3m=="5" 
replace g2=1 if GOS3m=="1" 
replace g2=1 if GOS3m=="2" 
replace g2=1 if GOS3m=="3" 
gen g3=. 
replace g3=0 if GOS6m=="4" 
replace g3=0 if GOS6m=="5" 
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replace g3=1 if GOS6m=="1" 
replace g3=1 if GOS6m=="2" 
replace g3=1 if GOS6m=="3" 
 
 
*generate obs 
gen obs=_n 
 
*transfer data from wide to long 
reshape long g, i(obs) j(time) 
 
*transfer time as 1, 3, 6 months (time2 as core covariate) 
gen time2=. 
replace time2=1 if time==1 
replace time2=3 if time==2 
replace time2=6 if time==3 
 
*transfer Age, Treatment, WFNS, Fisher, Hp from string to numeric data 
destring Age, gen(age) 
destring Treatment, gen(treatment) 
destring WFNS, gen(wfns) 
destring Fisher, gen(fisher) 
gen hpp=. 
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replace hpp=0 if Hp=="1" 
replace hpp=0 if Hp=="2" 
replace hpp=1 if Hp=="3" 
 
**logistic regression on Study E_unadj 
logistic g i.hpp if Study_ID=="E" 
 
**logistic regression on Study E_adj 
logistic g i.hpp diabetes htn a1 age i.treatment1 i.fisher i.wfns if Study_ID=="E" 
 
**sliding dichotomy for Study E 
logistic g i.treatment1  htn age i.fisher i.wfns if Study_ID=="E" 
predict phatE if Study_ID=="E" & time2==6 
xtile phate=phatE, nquantiles(3) 
gen dichotomy=. 
replace dichotomy=1 if Study_ID=="E"&(g==1|g==0)&time2==6 
replace dichotomy=0 if GOS6m=="5"& Study_ID=="E" & time2==6 
replace dichotomy=0 if GOS6m=="4"&Study_ID=="E" & time2==6 &(phate==2|phate==3) 
replace dichotomy=0 if GOS6m=="3"&Study_ID=="E" & time2==6 &(phate==3) 
**study E overall 
logistic dichotomy i.hpp i.treatment1 age i.fisher i.wfns if Study_ID=="E" 
 
**ordinal outcome 
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gen og=. 
replace og=2 if GOS30d=="4" & time2==1 
replace og=1 if GOS30d=="5" & time2==1 
replace og=3 if GOS30d=="3" & time2==1 
replace og=3 if GOS30d=="2" & time2==1 
replace og=3 if GOS30d=="1" & time2==1 
 
replace og=2 if GOS3m=="4" & time2==3 
replace og=1 if GOS3m=="5" & time2==3 
replace og=3 if GOS3m=="3" & time2==3 
replace og=3 if GOS3m=="2" & time2==3 
replace og=3 if GOS3m=="1" & time2==3 
 
replace og=2 if GOS6m=="4" & time2==6 
replace og=1 if GOS6m=="5" & time2==6 
replace og=3 if GOS6m=="3" & time2==6 
replace og=3 if GOS6m=="2" & time2==6 
replace og=3 if GOS6m=="1" & time2==6 
 
ologit og i.hpp i.treatment1 age i.fisher i.wfns diabetes a1 htn if Study_ID=="E", cluster(obs) or 
 
90 
APPENDIX C: RELEVANT STATA CODES (secondary outcome) 
import excel "D:\pitt\study\Project-Meta\part 2\IPLD_coded_combined_ANALYSIS_pitt_0801 
17 (1).xlsx", sheet("Data") firstrow clear 
 
drop if Treatment == 3 
gen hpp=. 
replace hpp=0 if Hp==1 
replace hpp=0 if Hp==2 
replace hpp=1 if Hp==3 
 
* cross-sectional analysis of secondary outcome without adjusted-DIND 
logit DIND i.hpp if Study_ID=="A", or 
logit DIND i.hpp if Study_ID=="B", or 
logit DIND i.hpp if Study_ID=="C", or 
logit DIND i.hpp if Study_ID=="D", or 
logit DIND i.hpp if Study_ID=="F", or 
logit DIND i.hpp if Study_ID=="G", or 
logit DIND i.hpp if Study_ID=="I", or 
logit DIND i.hpp if Study_ID=="K", or 
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* cross-sectional analysis of secondary outcome without adjusted-Ran_inf 
gen rad=. 
replace rad=0 if Rad_inf=="0" 
replace rad=1 if Rad_inf=="1" 
logit rad i.hpp if Study_ID=="A", or 
logit rad i.hpp if Study_ID=="B", or 
logit rad i.hpp if Study_ID=="C", or 
logit rad i.hpp if Study_ID=="D", or 
logit rad i.hpp if Study_ID=="G", or 
 
* cross-sectional analysis of secondary outcome without Def_VS 
logit Def_VS i.hpp if Study_ID=="A", or 
logit Def_VS i.hpp if Study_ID=="D", or 
logit Def_VS i.hpp if Study_ID=="E", or 
logit Def_VS i.hpp if Study_ID=="F", or 
logit Def_VS i.hpp if Study_ID=="G", or 
logit Def_VS i.hpp if Study_ID=="H", or 
logit Def_VS i.hpp if Study_ID=="I", or 
 
* cross-sectional analysis of secondary outcome without adjuasted--Angio_VS 
logit Angio_VS i.hpp if Study_ID=="B", or 
logit Angio_VS i.hpp if Study_ID=="C", or 
logit Angio_VS i.hpp if Study_ID=="D", or 
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logit Angio_VS i.hpp if Study_ID=="F", or 
logit Angio_VS i.hpp if Study_ID=="G", or 
logit Angio_VS i.hpp if Study_ID=="I", or 
logit Angio_VS i.hpp if Study_ID=="J", or 
logit Angio_VS i.hpp if Study_ID=="K", or 
 
***adjusted secondary outcome 
gen a1=. 
replace a1=1 if Aneurysm ==1 
replace a1=2 if Aneurysm ==2 
replace a1=3 if Aneurysm ==3 
replace a1=4 if Aneurysm ==4 
** cross-sectional analysis of secondary outcome with adjusted-DIND 
logit DIND i.hpp Age i.WFNS i.Treatment i.HTN if Study_ID=="A", or 
logit DIND i.hpp Age i.WFNS i.Treatment i.HTN if Study_ID=="B", or 
logit DIND i.hpp Age i.WFNS i.Treatment i.HTN if Study_ID=="C", or 
logit DIND i.hpp Age i.Fisher i.WFNS i.Treatment i.HTN if Study_ID=="D", or 
logit DIND i.hpp Age if Study_ID=="F", or 
logit DIND i.hpp Age i.WFNS i.Treatment i.HTN if Study_ID=="G", or 
logit DIND i.hpp Age i.Fisher i.WFNS i.Treatment i.HTN if Study_ID=="I", or 
logit DIND i.hpp Age i.Fisher i.Treatment i.HTN if Study_ID=="K", or 
* cross-sectional analysis of secondary outcome with adjusted-Ran_inf 
logit rad i.hpp i.a1 Age i.WFNS i.Treatment i.HTN if Study_ID=="A", or 
93 
logit rad i.hpp i.a1 Age i.WFNS i.Treatment i.HTN if Study_ID=="B", or 
logit rad i.hpp i.a1 Age i.WFNS i.Treatment i.HTN if Study_ID=="C", or 
logit rad i.hpp i.a1 Age i.WFNS i.Treatment i.HTN i.Fisher if Study_ID=="D", or 
logit rad i.hpp i.a1 Age i.WFNS i.Treatment i.HTN i.Fisher if Study_ID=="G", or 
* cross-sectional analysis of secondary outcome with adjusted_Def_VS 
logit Def_VS i.hpp Age i.HTN if Study_ID=="A", or 
logit Def_VS i.hpp Age i.WFNS i.Fisher i.Treatment i.HTN if Study_ID=="D", or 
logit Def_VS i.hpp Age i.WFNS i.Fisher i.Treatment i.HTN if Study_ID=="E", or 
logit Def_VS i.hpp Age i.WFNS i.Fisher i.Treatment i.HTN if Study_ID=="F", or 
logit Def_VS i.hpp Age i.HTN i.WFNS if Study_ID=="G", or 
logit Def_VS i.hpp Age if Study_ID=="H", or 
logit Def_VS i.hpp Age i.WFNS i.Fisher i.Treatment i.HTN if Study_ID=="I", or 
* cross-sectional analysis of secondary outcome with adjuasted--Angio_VS 
logit Angio_VS i.hpp Age i.WFNS i.Fisher i.Treatment i.HTN if Study_ID=="B", or 
logit Angio_VS i.hpp Age i.WFNS i.Fisher i.Treatment i.HTN if Study_ID=="C", or 
logit Angio_VS i.hpp Age i.WFNS i.Fisher i.Treatment i.HTN if Study_ID=="D", or 
logit Angio_VS i.hpp Age i.WFNS i.Fisher i.Treatment i.HTN if Study_ID=="F", or 
logit Angio_VS i.hpp Age i.WFNS i.Fisher i.Treatment i.HTN if Study_ID=="I", or 
logit Angio_VS i.hpp Age i.Treatment i.HTN if Study_ID=="J", or 
logit Angio_VS i.hpp Age i.Treatment i.HTN if Study_ID=="K", or 
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APPENDIX D: RELEVANT STATA CODES (Meta-analysis) 
** 22 vs 11&12 unadjusted 
clear 
 
set obs 8 
gen or=0 
gen lci=0 
gen uci=0 
gen name="" 
 
replace or=0.478 in 1/1 
replace or=1.267 in 2/2 
replace or=0.799 in 3/3 
replace or=1.195 in 4/4 
replace or=0.909 in 5/5 
replace or=0.725 in 6/6 
replace or=2.244 in 7/7 
replace or=1.549 in 8/8 
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replace lci=0.116 in 1/1 
replace lci=0.577 in 2/2 
replace lci=0.340 in 3/3 
replace lci=0.242 in 4/4 
replace lci=0.413 in 5/5 
replace lci=0.354 in 6/6 
replace lci=0.421 in 7/7 
replace lci=0.817 in 8/8 
 
replace uci=1.963 in 1/1 
replace uci=2.785 in 2/2 
replace uci=1.878 in 3/3 
replace uci=5.914 in 4/4 
replace uci=2.000 in 5/5 
replace uci=1.486 in 6/6 
replace uci=11.959 in 7/7 
replace uci=2.936 in 8/8 
 
replace name="Study A" in 1/1 
replace name="Study B" in 2/2 
replace name="Study C" in 3/3 
replace name="Study D" in 4/4 
replace name="Study E" in 5/5 
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replace name="Study F" in 6/6 
replace name="Study G" in 7/7 
replace name="Study I" in 8/8 
 
gen lnor=ln(or) 
gen lnlci=ln(lci) 
gen lnuci=ln(uci) 
metan lnor lnlci lnuci, eform effect(or) label(namevar=name) random 
 
metafunnel or lci uci, eform egger 
gen se=(lnuci-lnor)/1.96 
metabias lnor se,egger 
 
***22 vs 11&12 same covariates 
clear 
 
set obs 8 
gen or=0 
gen lci=o 
gen uci=0 
gen name="" 
 
replace or=0.467 in 1/1 
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replace or=1.001 in 2/2 
replace or=0.695 in 3/3 
replace or=1.017 in 4/4 
replace or=1.106 in 5/5 
replace or=0.672 in 6/6 
replace or=1.770 in 7/7 
replace or=0.994 in 8/8 
 
replace lci=0.085 in 1/1 
replace lci=0.116 in 2/2 
replace lci=0.281 in 3/3 
replace lci=0.100 in 4/4 
replace lci=0.450 in 5/5 
replace lci=0.262 in 6/6 
replace lci=0.338 in 7/7 
replace lci=0.454 in 8/8 
 
replace uci=2.571 in 1/1 
replace uci=8.628 in 2/2 
replace uci=1.723 in 3/3 
replace uci=10.363 in 4/4 
replace uci=2.722 in 5/5 
replace uci=1.725 in 6/6 
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replace uci=9.279 in 7/7 
replace uci=2.177 in 8/8 
 
replace name="Study A" in 1/1 
replace name="Study B" in 2/2 
replace name="Study C" in 3/3 
replace name="Study D" in 4/4 
replace name="Study E" in 5/5 
replace name="Study F" in 6/6 
replace name="Study G" in 7/7 
replace name="Study I" in 8/8 
 
gen lnor=ln(or) 
gen lnlci=ln(lci) 
gen lnuci=ln(uci) 
metan lnor lnlci lnuci, eform effect(or) label(namevar=name) random 
 
metafunnel or lci uci, eform egger 
 
gen se=(lnuci-lnor)/1.96 
metabias lnor se, egger 
 
***sliding dichotomy_same covariates 22 vs 11&12 
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clear 
 
set obs 6 
gen or=0 
gen lci=0 
gen uci=0 
gen name="" 
 
replace or=0.198 in 1/1 
replace or=2.633 in 2/2 
replace or=0.748 in 3/3 
replace or=1.219 in 4/4 
replace or=1.036 in 5/5 
replace or=0.957 in 6/6 
 
replace lci=0.039 in 1/1 
replace lci=0.960 in 2/2 
replace lci=0.294 in 3/3 
replace lci=0.568 in 4/4 
replace lci=0.380 in 5/5 
replace lci=0.409 in 6/6 
 
replace uci=1.005 in 1/1 
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replace uci=7.223 in 2/2 
replace uci=1.907 in 3/3 
replace uci=2.619 in 4/4 
replace uci=2.824 in 5/5 
replace uci=2.241 in 6/6 
 
replace name="Study A" in 1/1 
replace name="Study B" in 2/2 
replace name="Study C" in 3/3 
replace name="Study E" in 4/4 
replace name="Study F" in 5/5 
replace name="Study I" in 6/6 
 
gen lnor=ln(or) 
gen lnlci=ln(lci) 
gen lnuci=ln(uci) 
metan lnor lnlci lnuci, eform effect(or) label(namevar=name) random 
 
metafunnel or lci uci, eform egger 
gen se=(lnuci-lnor)/1.96 
metabias lnor se, egger 
 
***ordinal_22vs11&12_same 
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clear 
 
set obs 8 
gen or=0 
gen lci=0 
gen uci=0 
gen name="" 
 
replace or=0.315 in 1/1 
replace or=0.988 in 2/2 
replace or=0.799 in 3/3 
replace or=2.298 in 4/4 
replace or=1.356 in 5/5 
replace or=0.694 in 6/6 
replace or=0.746 in 7/7 
replace or=0.823 in 8/8 
 
replace lci=0.073 in 1/1 
replace lci=0.448 in 2/2 
replace lci=0.353 in 3/3 
replace lci=0.527 in 4/4 
replace lci=0.721 in 5/5 
replace lci=0.353 in 6/6 
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replace lci=0.203 in 7/7 
replace lci=0.464 in 8/8 
 
replace uci=1.354 in 1/1 
replace uci=2.181 in 2/2 
replace uci=1.810 in 3/3 
replace uci=10.020 in 4/4 
replace uci=2.550 in 5/5 
replace uci=1.365 in 6/6 
replace uci=2.744 in 7/7 
replace uci=1.462 in 8/8 
 
replace name="Study A" in 1/1 
replace name="Study B" in 2/2 
replace name="Study C" in 3/3 
replace name="Study D" in 4/4 
replace name="Study E" in 5/5 
replace name="Study F" in 6/6 
replace name="Study G" in 7/7 
replace name="Study I" in 8/8 
 
gen lnor=ln(or) 
gen lnlci=ln(lci) 
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gen lnuci=ln(uci) 
metan lnor lnlci lnuci, eform effect(or) label(namevar=name) random 
 
metafunnel or lci uci, eform egger 
gen se=(lnuci-lnor)/1.96 
metabias lnor se, egger 
 
**DIND 22 VS 11&12 unadjusted 
clear 
 
set obs 6 
gen or=0 
gen lci=0 
gen uci=0 
gen name="" 
 
replace or=0.545 in 1/1 
replace or=2.458 in 2/2 
replace or=1.367 in 3/3 
replace or=0.844 in 4/4 
replace or=1.45 in 5/5 
replace or=1.335 in 6/6 
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replace lci=0.093 in 1/1 
replace lci=0.897 in 2/2 
replace lci=0.522 in 3/3 
replace lci=0.219 in 4/4 
replace lci=0.236 in 5/5 
replace lci=0.716 in 6/6 
 
replace uci=3.194 in 1/1 
replace uci=6.736 in 2/2 
replace uci=3.578 in 3/3 
replace uci=3.255 in 4/4 
replace uci=8.923 in 5/5 
replace uci=2.488 in 6/6 
 
replace name="Study A" in 1/1 
replace name="Study B" in 2/2 
replace name="Study C" in 3/3 
replace name="Study D" in 4/4 
replace name="Study G" in 5/5 
replace name="Study I" in 6/6 
 
gen lnor=ln(or) 
gen lnlci=ln(lci) 
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gen lnuci=ln(uci) 
metan lnor lnlci lnuci, eform effect(or) label(namevar=name) 
 
metafunnel or lci uci, eform egger 
gen se=(lnuci-lnor)/1.96 
metabias lnor se, egger 
 
***DIND 22vs11&21_same  
clear 
 
set obs 8 
gen or=0 
gen lci=0 
gen uci=0 
gen name="" 
 
replace or=0.455 in 1/1 
replace or=2.201 in 2/2 
replace or=1.556 in 3/3 
replace or=0.690 in 4/4 
replace or=1.566 in 5/5 
replace or=1.788 in 6/6 
replace or=0.907 in 7/7 
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replace or=0.393 in 8/8 
 
replace lci=0.070 in 1/1 
replace lci=0.772 in 2/2 
replace lci=0.551 in 3/3 
replace lci=0.146 in 4/4 
replace lci=0.062 in 5/5 
replace lci=0.248 in 6/6 
replace lci=0.430 in 7/7 
replace lci=0.027 in 8/8 
 
replace uci=2.947 in 1/1 
replace uci=6.274 in 2/2 
replace uci=4.395 in 3/3 
replace uci=3.263 in 4/4 
replace uci=39.515 in 5/5 
replace uci=12.884 in 6/6 
replace uci=1.912 in 7/7 
replace uci=5.584 in 8/8 
 
replace name="Study A" in 1/1 
replace name="Study B" in 2/2 
replace name="Study C" in 3/3 
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replace name="Study D" in 4/4 
replace name="Study F" in 5/5 
replace name="Study G" in 6/6 
replace name="Study I" in 7/7 
replace name="Study K" in 8/8 
 
gen lnor=ln(or) 
gen lnlci=ln(lci) 
gen lnuci=ln(uci) 
metan lnor lnlci lnuci, eform effect(or) label(namevar=name) random 
 
metafunnel or lci uci, eform egger 
gen se=(lnuci-lnor)/1.96 
metabias lnor se, egger 
 
**Rad_inf 11&12vs22-unadjusted 
clear 
 
set obs 5 
gen or=0 
gen lci=0 
gen uci=0 
gen name="" 
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replace or=0.900 in 1/1 
replace or=2.103 in 2/2 
replace or=0.652 in 3/3 
replace or=1.25 in 4/4 
replace or=1.26 in 5/5 
 
replace lci=0.184 in 1/1 
replace lci=0.659 in 2/2 
replace lci=0.161 in 3/3 
replace lci=0.316 in 4/4 
replace lci=0.248 in 5/5 
 
replace uci=4.400 in 1/1 
replace uci=6.704 in 2/2 
replace uci=2.644 in 3/3 
replace uci=4.940 in 4/4 
replace uci=6.446 in 5/5 
 
replace name="Study A" in 1/1 
replace name="Study B" in 2/2 
replace name="Study C" in 3/3 
replace name="Study D" in 4/4 
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replace name="Study G" in 5/5 
 
gen lnor=ln(or) 
gen lnlci=ln(lci) 
gen lnuci=ln(uci) 
metan lnor lnlci lnuci, eform effect(or) label(namevar=name) random 
 
metafunnel or lci uci, eform egger 
gen se=(lnuci-lnor)/1.96 
metabias lnor se, egger 
 
***Rad_inf_22 vs 11 & 12_same covariates 
clear 
 
set obs 5 
gen or=0 
gen lci=0 
gen uci=0 
gen name="" 
 
replace or=1.027 in 1/1 
replace or=1.934 in 2/2 
replace or=0.832 in 3/3 
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replace or=1.390 in 4/4 
replace or=0.905 in 5/5 
 
replace lci=0.176 in 1/1 
replace lci=0.573 in 2/2 
replace lci=0.183 in 3/3 
replace lci=0.296 in 4/4 
replace lci=0.136 in 5/5 
 
replace uci=6.013 in 1/1 
replace uci=6.533 in 2/2 
replace uci=3.773 in 3/3 
replace uci=6.535 in 4/4 
replace uci=5.999 in 5/5 
 
replace name="Study A" in 1/1 
replace name="Study B" in 2/2 
replace name="Study C" in 3/3 
replace name="Study D" in 4/4 
replace name="Study G" in 5/5 
 
gen lnor=ln(or) 
gen lnlci=ln(lci) 
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gen lnuci=ln(uci) 
metan lnor lnlci lnuci, eform effect(or) label(namevar=name) random 
 
metafunnel or lci uci, eform egger 
gen se=(lnuci-lnor)/1.96 
metabias lnor se, egger 
 
***Def_VS 22vs11&12 same covariates 
clear 
 
set obs 7 
gen or=0 
gen lci=0 
gen uci=0 
gen name="" 
 
replace or=0.463 in 1/1 
replace or=0.978 in 2/2 
replace or=0.715 in 3/3 
replace or=0.669 in 4/4 
replace or=4.518 in 5/5 
replace or=0.454 in 6/6 
replace or=1.079 in 7/7 
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replace lci=0.041 in 1/1 
replace lci=0.125 in 2/2 
replace lci=0.256 in 3/3 
replace lci=0.270 in 4/4 
replace lci=0.237 in 5/5 
replace lci=0.040 in 6/6 
replace lci=0.525 in 7/7 
 
replace uci=5.279 in 1/1 
replace uci=7.619 in 2/2 
replace uci=2.000 in 3/3 
replace uci=1.657 in 4/4 
replace uci=85.951 in 5/5 
replace uci=5.139 in 6/6 
replace uci=2.218 in 7/7 
 
replace name="Study A" in 1/1 
replace name="Study D" in 2/2 
replace name="Study E" in 3/3 
replace name="Study F" in 4/4 
replace name="Study G" in 5/5 
replace name="Study H" in 6/6 
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replace name="Study I" in 7/7 
 
gen lnor=ln(or) 
gen lnlci=ln(lci) 
gen lnuci=ln(uci) 
metan lnor lnlci lnuci, eform effect(or) label(namevar=name) random 
 
metafunnel or lci uci, eform egger 
gen se=(lnuci-lnor)/1.96 
metabias lnor se, egger 
 
***Def_VS 22vs11&12 same covariates 
clear 
 
set obs 7 
gen or=0 
gen lci=0 
gen uci=0 
gen name="" 
 
replace or=0.463 in 1/1 
replace or=0.978 in 2/2 
replace or=0.715 in 3/3 
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replace or=0.669 in 4/4 
replace or=4.518 in 5/5 
replace or=0.454 in 6/6 
replace or=1.079 in 7/7 
 
replace lci=0.041 in 1/1 
replace lci=0.125 in 2/2 
replace lci=0.256 in 3/3 
replace lci=0.270 in 4/4 
replace lci=0.237 in 5/5 
replace lci=0.040 in 6/6 
replace lci=0.525 in 7/7 
 
replace uci=5.279 in 1/1 
replace uci=7.619 in 2/2 
replace uci=2.000 in 3/3 
replace uci=1.657 in 4/4 
replace uci=85.951 in 5/5 
replace uci=5.139 in 6/6 
replace uci=2.218 in 7/7 
 
replace name="Study A" in 1/1 
replace name="Study D" in 2/2 
115 
replace name="Study E" in 3/3 
replace name="Study F" in 4/4 
replace name="Study G" in 5/5 
replace name="Study H" in 6/6 
replace name="Study I" in 7/7 
 
gen lnor=ln(or) 
gen lnlci=ln(lci) 
gen lnuci=ln(uci) 
metan lnor lnlci lnuci, eform effect(or) label(namevar=name) random 
 
metafunnel or lci uci, eform egger 
gen se=(lnuci-lnor)/1.96 
metabias lnor se, egger 
 
**Angio_VS 11 & 12 vs 22-unadjusted 
clear 
 
set obs 7 
gen or=0 
gen lci=0 
gen uci=0 
gen name="" 
116 
 
replace or=3.597 in 1/1 
replace or=1.623 in 2/2 
replace or=0.844 in 3/3 
replace or=1.097 in 4/4 
replace or=0.620 in 5/5 
replace or=2 in 6/6 
replace or=1.333 in 7/7 
 
replace lci=1.492 in 1/1 
replace lci=0.514 in 2/2 
replace lci=0.219 in 3/3 
replace lci=0.456 in 4/4 
replace lci=0.277 in 5/5 
replace lci=0.324 in 6/6 
replace lci=0.165 in 7/7 
 
replace uci=8.668 in 1/1 
replace uci=5.125 in 2/2 
replace uci=3.255 in 3/3 
replace uci=2.638 in 4/4 
replace uci=1.387 in 5/5 
replace uci=12.329 in 6/6 
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replace uci=10.743 in 7/7 
 
replace name="Study B" in 1/1 
replace name="Study C" in 2/2 
replace name="Study D" in 3/3 
replace name="Study F" in 4/4 
replace name="Study I" in 5/5 
replace name="Study J" in 6/6 
replace name="Study K" in 7/7 
 
gen lnor=ln(or) 
gen lnlci=ln(lci) 
gen lnuci=ln(uci) 
metan lnor lnlci lnuci, eform effect(or) label(namevar=name) random 
 
metafunnel or lci uci, eform egger 
gen se=(lnuci-lnor)/1.96 
metabias lnor se, egger 
 
***Angio_vs 22vs11&12 same covariates 
clear 
 
set obs 7 
118 
gen or=0 
gen lci=0 
gen uci=0 
gen name="" 
 
replace or=3.268 in 1/1 
replace or=2.203 in 2/2 
replace or=0.690 in 3/3 
replace or=0.776 in 4/4 
replace or=0.452 in 5/5 
replace or=1.834 in 6/6 
replace or=0.453 in 7/7 
 
replace lci=1.293 in 1/1 
replace lci=0.612 in 2/2 
replace lci=0.146 in 3/3 
replace lci=0.265 in 4/4 
replace lci=0.182 in 5/5 
replace lci=0.221 in 6/6 
replace lci=0.033 in 7/7 
 
replace uci=8.262 in 1/1 
replace uci=7.936 in 2/2 
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replace uci=3.263 in 3/3 
replace uci=2.273 in 4/4 
replace uci=1.122 in 5/5 
replace uci=15.176 in 6/6 
replace uci=6.294 in 7/7 
 
replace name="Study B" in 1/1 
replace name="Study C" in 2/2 
replace name="Study D" in 3/3 
replace name="Study F" in 4/4 
replace name="Study I" in 5/5 
replace name="Study J" in 6/6 
replace name="Study K" in 7/7 
 
gen lnor=ln(or) 
gen lnlci=ln(lci) 
gen lnuci=ln(uci) 
metan lnor lnlci lnuci, eform effect(or) label(namevar=name) random 
 
metafunnel or lci uci, eform egger 
gen se=(lnuci-lnor)/1.96 
metabias lnor se, egger 
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APPENDIX E: RELEVANT STATA CODES (one-stage analysis) 
 
**primary outcome  
gen primary=. 
replace primary=m 
replace primary=g if Study_ID=="E" 
**unadjusted 
melogit primary i.hpp ||obs:,||Study_ID:, or 
**adjusted 
melogit primary i.hpp age i.wfns i.treatment||obs:,||Study_ID:, or 
 
**secondary outcome 
***one-stage unadj 
melogit DIND i.hpp ||Study_ID:, or 
melogit rad i.hpp ||Study_ID:, or 
melogit Angio_VS i.hpp||Study_ID:, or 
melogit Def_VS i.hpp||Study_ID:, or 
melogit second i.hpp||Study_ID:, or 
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***one-stage adj 
melogit DIND i.hpp Age i.WFNS i.Treatment i.HTN ||Study_ID:,or 
melogit rad i.hpp Age i.WFNS i.Treatment i.HTN ||Study_ID:,or 
melogit Angio_VS i.hpp Age i.WFNS i.Treatment i.HTN ||Study_ID:,or 
melogit Def_VS i.hpp Age i.WFNS i.Treatment i.HTN ||Study_ID:,or 
melogit second i.hpp Age i.WFNS i.Treatment i.HTN ||Study_ID:,or 
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